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ABSTRACT 
 
The present work describes studies aimed at characterizing enzymes involved in 
bacterial metabolic pathways using a variety of biochemical methods, analytical 
techniques and structural studies. The first study explains the structural and biochemical 
characterization of a C-glycosidase involved in pseudouridine catabolic pathway. Our 
studies suggested that its mechanism is significantly different from the previously 
reported glycosidases. The second study describes the discovery and mechanistic 
characterization of a radical SAM enzyme involved in a new menaquinone biosynthetic 
pathway. This enzyme represents a unique reaction motif in radical SAM enzymology. 
 
Pseudouridine (Ψ), the most abundant modification in RNA, is synthesized using Ψ 
synthase. Recently, a pathway for the degradation of Ψ was described in Escherichia 
coli. In this pathway, Ψ is first converted to Ψ 5′-monophosphate (ΨMP) by Ψ kinase 
and then ΨMP is degraded by ΨMP glycosidase to uracil and ribose 5- phosphate. The 
structural studies on the ΨMP glycosidase and its mutant (K166A) suggested that the 
reaction utilizes a Lys166-substrate adduct during catalysis. Biochemical studies on 
ΨMP glycosidase further confirmed the existence of a lysine adduct and allowed us to 
identify roles for specific active site residues. ΨMP glycosidase catalyzes the cleavage of 
the C−C glycosidic bond through a novel ribose ring-opening mechanism. This is the 
first mechanistically characterized C-glycosidase. 
 
 iii 
 
Menaquinone (MK, vitamin K2) is a lipid soluble molecule that participates in the 
bacterial electron transport chain. In mammalian cells, MK functions as an essential 
vitamin for the activation of various proteins involved in blood clotting and bone 
metabolism. Recently, a new pathway for the biosynthesis of this cofactor was 
discovered in Streptomyces coelicolor A3(2) in which chorismate is converted to 
aminofutalosine in a reaction catalyzed by MqnA and an unidentified enzyme. Here, we 
reconstitute the biosynthesis of aminofutalosine and demonstrate that the missing 
enzyme (aminofutalosine synthase, MqnE) is a radical SAM enzyme that catalyzes the 
addition of the adenosyl radical to the double bond of 3-[(1-carboxyvinyl) oxy] benzoic 
acid. This is a new reaction type in the radical SAM superfamily. The substrate analogs 
based mechanistic investigation suggested that MqnE catalyzes a unique radical 
rearrangement reaction, unprecedented in biological chemistry. 
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NOMENCLATURE 
 
Ѱ Pseudouridine 
ѰMP Pseudouridine-5’monophosphate 
R5P                             Ribose-5-phosphate 
Ura                              Uracil 
ATP                            Adenosyl 5’-triphosphate 
MK Menaquionone 
OSB                            O-succinyl benzoate 
NADH                         β-nicotinamide adenine dinucleotide, reduced form 
NADPH                      β-nicotinamide adenine dinucleotide phosphate, reduced form 
DHNA                        1,4-dihydroxy-2-naphthoate 
SAM                           S-Adenosyl-L-Methionine 
TPP                             Thiamine pyrophosphate 
Tris                              tris-(hydroxymethyl) aminomethane 
DHFL                          dehypoxanthine futalosine 
cDHFL                        cyclic dehypoxanthine futalosine 
PEP                             phosphoenolpyruvate 
NMR                           Nuclear Magnetic Resonance 
HPLC                         High Performance Liquid Chromatography 
LC-MS                       Liquid Chromatography-Mass Spectrometry 
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CHAPTER I 
INTRODUCTION: BIOSYNTHESIS AND CATABOLISM OF 
PSEUDOURIDINE 
Introduction 
Pseudouridine (5-ribosyluracil, Ψ), 2 was the first modified nucleoside to be discovered 
and is the most abundant modification in RNA, existing in tRNAs, rRNAs, snRNAs, and 
snoRNAs.
1
 Ψ is biosynthesized post-transcriptionally from RNA uridine moieties, 1 by a
class of enzymes called pseudouridine synthase (Ψ synthase), which cleaves the 
glycosidic C−N bond and reconnects the uracil to the ribosyl moiety at the C5 position 
(Figure 1.1).
2
 Pseudouridine reduces the conformational flexibility of RNA because the
exposed, protonated N1 atom forms strong hydrogen bonds with structured water 
molecules, replacing weak interactions formed by C5 in uridine. Ψ in RNA provides the 
appropriate geometry and distance for coordination for a water molecule between its N1-
H and the 5’-phosphates of both Ψ and the preceding residue forming a hydrogen bond. 
This restricts base conformation and mobility of backbone 5’ to the site of 
pseudouridylation and also enhances base stacking.
1, 3 
Figure 1.1: Biosynthesis of pseudouridine 
2 
Mammalian rRNA contains about 100 pseudouridines per ribosome and tRNAs contain 
an average of 3-4 of them.
1
 Ψ is found in almost all tRNAs, at a notably universal
position namely Ψ55, after which the T ΨC stem-loop is named (Figure 1.2). Other 
positions of tRNA at which it occurs in all three domains of life (archaebacterial, 
eubacteria and eukaryotes) as well as in organelles (such as mitochondria and 
chloroplasts) include the D stem and the anticodon stem and loop (ASL).
1
 Ψ contributes
to the stabilization of the specific structural motifs in which it occurs (Figure 2): for 
instance, the T ΨC loop (Ψ55), the D stem (Ψ13), the anticodon stem (features a strong 
closing base pair between Ψ39 and A31) and the anticodon loop (noncanonical or 
pseudo base-pairing between Ψ38 and residue 32).4, 5 
Figure 1.2: Distribution of Ψ residues in tRNA4
3 
Biological role of pseudouridine 
Through its unique ability to coordinate a structural water molecule via the free N1-H, Ψ 
exerts a subtle but significant rigidifying influence on the nearby sugar phosphate 
backbone in tRNA and also enhances base stacking. These effects of may underlie the 
biological role of most of the Ψ residues in RNA. During translation, Ψ is thought to 
modulate several interactions that tRNA molecules make with rRNAs and with mRNAs. 
The influence of modified nucleosides, like Ψ, on the local structure of the anticodon 
stem and loop (ASL) appears to be critical for the proper binding of tRNA to the 
ribosome (30S ribosomal subunit) which helps to foster correct codon-anticodon 
interactions.
6-10
 This may increase the translational accuracy by decreasing the rate of
peptide bond formation, thereby allowing more time for rejection of incorrect codon-
anticodon pairs.
11
 This improves the fidelity of protein biosynthesis. Ψ residues may also
influence both rRNA folding and ribosome assembly.
12, 13
 In the mature ribosome, Ψ
probably contributes to the stabilization of local secondary or tertiary structure through 
RNA-RNA or RNA-protein interactions.
14
 This fine tuning of the local higher order
structure in rRNA could influence the speed and accuracy of decoding and proofreading 
during translation by fostering appropriate interactions with tRNA.
15
It was observed that certain genetic mutants lacking specific Ψ residues in tRNA or 
rRNA exihibit difficulties in translation, display slow growth rates and fail to compete 
effectively with the wild-type strains in mixed culture.
1
 In particular, normal growth is
severely compromised in an Escherichia coli mutant deficient in a pseudouridine 
4 
synthase responsible for the formation of three closely spaced Ψ residues (Ψ1911, 
Ψ1915 and Ψ 1917) in the mRNA decoding region of the 23S rRNA.16 The loss of
function by homologues of a nuclear pseudouridine synthase in yeast (Cbf5p), 
Drosophila (mfl), rats (NAP57) and humans (dyskerin) leads to phenotypes ranging 
from severe physiological impairment to lethality.
17-21
 For example, mutations in the
human gene encoding dyskerin have been associated with the rare haematopoietic and 
malignant disorder, X-linked dyskeratosis congenita.
19, 22
 Hence, these studies indicate
that pseudouridylation of RNA
23
 is an important event which confers a selective
advantage in a biological context. 
Biosynthesis of pseudouridine 
The pseudouridine synthases (Ψ synthases) isomerize uridine to pseudouridine in RNA 
and fall into six families.
24-26
 Despite their insignificant global sequence similarity, the
families share a common protein fold with a core β sheet and constellation of active site 
residues as evident from their crystal structures.
27
 An active site Asp is the only amino
acid conserved among all Ψ synthases and it is found to be essential for catalytic activity 
suggesting that this family of enzymes share a common mechanism.
28, 29
 The mechanism
for this enzyme is proposed based on several biochemical and structural studies using 
substrate analogs such as 5-fluorouridine and [F
5
U]-RNA.
28, 29
However, a recent 
mechanistic proposal is put forward for pseudouridine synthase TruB from E. coli. 
(Figure 1.3).
30
 The N-glycosyl bond in uridine 1 cleaves forming the oxocarbenium ion,
3 and uracil anion, 4. The active site Asp residue traps the oxocarbenium ion forming an 
 5 
 
 
enzyme covalent adduct, 5 at C1’ while the uracil anion undergoes an 1800 rotation to 
juxtapose C5 of pyrimidine and C1’ of the ribosyl moiety. This is followed by formation 
of the C1’-C5 glycosidic bond by the attack from the uracil anion on to the enzyme 
covalent adduct, forming 6. A final tautomerization step probably assisted by the active 
site Asp lead to the formation of pseudouridine 2. 
 
 
Figure 1.3: Mechanistic proposal for pseudouridine synthase. 
 
Catabolism of pseudouridine 
While Ψ biosynthesis has been studied extensively, little is known about Ψ catabolism.  
It is one of the few examples of molecules that have a glycosidic C-C bond. Other 
examples of such nucleosides include C-mannosyl residues bound to tryptophan
31
 
(mannosyltryptophan, 7, Figure 1.4), the C-glucosides bound to catechol derivatives (C-
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glucosylated form of microcin E492)
32
 and some nucleoside analogues such as formycin 
A
33
 (8, Figure 1.4). However, no enzyme that cleaves a C-C glycosidic bond is 
mechanistically characterized. 
 
 
Figure 1.4: Examples of other C-glycosides  
 
It was reported that Ψ can be used by E. coli as a source of uracil for a strain deficient in 
pyrimidine synthesis (uridine auxotroph).
34
 Ψ was shown to be phosphorylated in E. coli 
extracts by a kinase to pseudouridine 5’-phosphate (pseudouridine monophosphate, 
ΨMP) 35 which is further hydrolyzed to ribose-5-phosphate and uracil.36 However, none 
of these enzymes were identified. Recently, the two enzymes responsible for Ψ 
degradation in E. coli were identified and their molecular characterization was 
achieved.
37
 Ψ kinase (YeiC) first phosphorylates Ψ to pseudouridine 5´-monophosphate, 
9 (ΨMP), with the help of adenosine triphosphate (ATP) and Mg2+. ΨMP glycosidase 
(YeiN) then catalyzes the reversible cleavage of the C-C glycosidic bond to form ribose 
5-phosphate, 10 (R5P) and uracil, 11 (Figure 1.5) and requires divalent metal ions such 
as Mn
2+
 for its activity. While ΨMP glycosidase functions biologically in the cleavage 
direction, equilibrium strongly favors ΨMP synthesis with an equilibrium constant for 
7 
the degradation reaction of 2.3×10
-4
.
37
 In bacterial genomes Ψ kinase and ΨMP
glycosidase are encoded by separate genes.  In E. coli these are yeiC and yeiN, 
respectively, which are located in the same operon (Figure 1.6).
37
 In some eukaryotes,
the genes for Ψ kinase and ΨMP glycosidase are fused resulting in a bifunctional 
enzyme (Figure 1.6).
37
 Enzymes metabolizing Ψ are not found in humans and most other
higher organisms suggesting that Ψ is not metabolized in them and excreted in urine.38 
Figure 1.5: Catabolic pathway of pseudouridine 
Figure 1.6: Organization of the genes involved in pseudouridine catabolism. 
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YeiN is the first molecularly identified enzyme that catalyzes a mechanistically 
intriguing hydrolytic cleavage of a glycosidic C-C bond. 
 
Glycosidase mechanisms 
While natural products containing O and N glycosidic bonds are widespread, natural 
products containing the C-glycosidic bond are much less prevalent.
39
 The C-glycosidic 
bond is generally formed by an electrophilic aromatic substitution on an electron rich 
double bond. Enzymes that cleave C-N glycosidic bonds have been extensively studied.  
These include nucleoside and nucleotide hydrolases,
40-42
 purine and pyrimidine 
nucleoside phosphorylases,
43
 purine and pyrimidine phosphoribosyltransferases,
44, 45
 and 
nucleoside deoxyribosyltransferases.
46
 In addition to them, DNA repair enzymes such as 
endonuclease III also function as N- glycosylases to remove damaged nucleobases from 
DNA.
47
 On the other hand, enzymes that cleave C-O glycosidic bonds are widespread in 
carbohydrate metabolism and have also been extensively studied mechanistically.
48, 49
 
Biochemical, biophysical and genetic studies suggest that these enzymes cleave C-N and 
C-O glycosidic bonds by a largely dissociative mechanism generating an oxocarbenium 
ion intermediate. General mechanisms for glycosidases cleaving C-O glycosidic bonds
49
 
are shown in Figure 1.7.  
 
However, although the genes encoding several C-glycosynthases have been identified 
and overexpressed
50-57
 and the structures of ligand free C-C bond forming 
glycosyltransferase, UrdGT2
58, 59
 and ligand free C-glycosidase TM1464 from 
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Thermotoga maritima (an Indigoidine synthase, IndA or ΨMP glycosidase, YeiN like 
protein) have been determined
60
, yet there is currently no example of a mechanistically 
well characterized C-glycosidase or glycosynthase. 
 
 
Figure 1.7: General mechanisms for inverting (A) and retaining (B) glycosidases 
 
Research opportunity 
From the above discussion, it is clear that, although there are reports of several naturally 
occurring C-glycosides, there is currently no example of a mechanistically well-
characterized C-glycosidase. Recently identified ΨMP glycosidase (YeiN) represents 
one such case where biochemical and structural studies would lead to the understanding 
of the underlying mechanism of this kind of glycosidases. Moreover, it was observed 
that unlike the C-O and C-N bond cleaving glycosidases, YeiN shows metal ion cofactor 
 10 
 
 
dependence. Hence, it will be interesting to know how different its mechanism would be 
from the well-established mechanisms of previously characterized glycosidases. The 
studies described herein are aimed at understanding the mechanism of the first ever 
identified C-C glycosidic bond cleaving enzyme (Figure 1.5). 
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CHAPTER II 
PSEUDOURIDINE CATABOLISM: STUDIES ON THE PSEUDOURIDINE 
MONOPHOSPHATE (ΨMP) GLYCOSIDASE, YeiN *# 
Introduction 
The pseudouridine (Ψ) catabolic pathway was discovered in E. coli.37 In this pathway,
pseudouridine kinase (YeiC) first phosphorylates the 5’-hydroxyl group of 
pseudouridine forming ΨMP. Then  ΨMP glycosidase (YeiN) catalyzes the reversible 
conversion of ΨMP, 9 to ribose 5 phosphate, 10 and uracil, 11 (Figure 1.5). Based on the 
mechanism of Ψ synthase, we have a mechanistic proposal for YeiN (Figure 2.1). 
Figure 2.1: Mechanistic proposal for the ΨMP glycosidase, YeiN. 
*Part of this chapter is reprinted with permission from “Pseudouridine Monophosphate
Glycosidase: A New Glycosidase Mechanism” by Huang, S.; Mahanta, N.; Begley, T. P.; Ealick, 
S. E., 2012. Biochemistry, 51, 9245-9255, Copyright [2012] by American Chemical Society. 
#
(Siyu Huang performed all the structural work shown here. Nilkamal Mahanta carried out all the 
biochemical studies. Cynthia Kinsland cloned YeiN and its mutants). 
______________
12 
In this proposal, an acid-base residue assisted tautomerization would convert 9 to 16, 
followed by the glycosidic bond cleavage in the latter, leading to the oxocarbenium ion 
intermediate 17 and uracil anion, 4. Then 17 may be trapped by an enzyme active site 
residue (like Asp in Figure 1.3) forming a covalent enzyme-substrate adduct which may 
be further hydrolyzed to form ribose-5-phosphate, 10. The uracil anion, after protonation 
would yield uracil, 11. To investigate the mechanism of the glycosidase reaction and test 
the validity of our hypothesis, structural studies and biochemical experiments were 
carried out on YeiN. Interestingly, our results suggested a novel mechanism for ΨMP 
glycosidase, involving an covalent adduct between an active site lysine residue and C1’ 
of the sugar moiety of the substrate during catalysis.
61 
Results and discussion 
HPLC analysis of the reaction mixture: Since, the YeiN catalyzed reaction is 
reversible; the reverse reaction was analyzed by high performance liquid 
chromatography in order to reconstitute the YeiN activity. Uracil (1mM) and ribose-5-
phosphate, R5P (1mM) was incubated with YeiN (50 µM) in Tris-HCl buffer (pH 8.0) in 
presence of divalent metal ions (Mn
2+ 
and Co
2+
, 1mM). Formation of a new compound at
2.1 min in the HPLC chromatogram was observed (Figure 2.2) and further confirmation 
by coupled YeiC and YeiN assay (Figures A1 and A2, Appendix A) and mass 
spectrometry and NMR spectroscopy (Figures A3 and A4, Appendix A) suggested that 
ΨMP is formed in the YeiN assay confirming the enzyme activity. This allowed us to 
carry on with further biochemical and structural studies on YeiN. 
13 
Figure 2.2: HPLC analysis of the YeiN reaction mixture. 
[Blue trace: chromatogram of the full reaction mixture (YeiN+ R5P, 10 + Uracil, 11 + 
Co
2+
) Red trace: chromatogram of the full reaction mixture (YeiN+ R5P, 10 + Uracil, 11
+ Mn
2+
). Both of them show the production of ΨMP, 9 at 2.1 min. Green trace:
chromatogram of the control reaction mixture lacking substrate 10. Purple trace: 
chromatogram of the authentic standard for uracil 11.] 
Overall structure of the ΨMP glycosidase: ΨMP glycosidase is a homotrimer61 (Figure
2.3A) with one trimer per asymmetric unit in the crystal structure. Of the 312 possible 
residues, each protomer is complete except for the first two to five residues at the N-
terminus and the C-terminal residue, which is missing in most of the protomers. ΨMP 
glycosidase shows a αβα fold. The central mixed β-sheet contains 11strands with 
1↑4↑3↓2↓7↓8↓11↓9↓10↓5↑6↑ topology and is flanked by six α-helices on one side and 
seven α-helices on the other (Figure 2.3 B, C).61 The trimer contains a buried surface
area of 8650 Å2, accounting for 27.8% of the total surface area. The trimer interface is 
Uracil, 11
ΨMP, 9 
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formed primarily by helices α5 and α8 from one protomer and helices α9 and α10 from 
the adjacent protomer. The interface includes hydrogen bonds between Ile146 and 
Thr180* (an asterisk indicates residues from an adjacent protomer) and between Arg96 
and Asn228*, and a salt bridge between Arg97 and Glu179*. 
Figure 2.3: Structure of the ΨMP glycosidase.61
[(A) Ribbon diagram of the ΨMP glycosidase trimer color-coded by protomer and the 
active site is indicated by the space filling model. The Mn (II) ion is colored purple. (B) 
Ribbon diagram of a ΨMP glycosidase protomer labeled with color-coded α-helices 
(blue) and β-strands (green). (C) Topology diagram of ΨMP glycosidase. The green 
arrows represent β-strands and blue cylinders α-helices. The first residue number and the 
last residue number of each secondary structural element are indicated]. 
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Mn (II) binding site:  Mn (II) is required for ΨMP glycosidase activity37 and for the
formation of high-quality crystals. The Mn (II) coordination is octahedral with Mn 
(II)−oxygen distances ranging from 2.13 to 2.35 Å (Figure 2.4). Only one protein 
residue, Asp145, participates in coordination, and water molecules (W1−W5) occupy the 
five remaining positions. The coordinating oxygen atoms interact with protein atoms, 
substrate atoms (Figure 2.4), and other water molecules.W1 hydrogen bonds to Glu179* 
and a ΨMP phosphate oxygen atom.W2 hydrogen bonds to His137 and a ΨMP 
phosphate oxygen atom.W3 hydrogen bonds to Asp145 and the carbonyl oxygen atom of 
Gly266.W4 hydrogen bonds to Glu176* and Glu179*. W5 hydrogen bonds to a water 
molecule in the second sphere (W11) and a water molecule (W7) that bridges to the 
ΨMP phosphate. The water molecules directly involved in Mn (II) interactions are 
involved in additional hydrogen bonding interactions that extend into the remainder of 
the active site. In Figure 2.4, water molecules and protein atoms in the first and second 
coordination spheres are shown. The sulfate ion results from the crystallization 
conditions and occupies the phosphate binding site. 
16 
Figure 2.4: Stereoview of the Mn (II) binding site.
61
Structure of the ΨMP glycosidase−ring-opened ribose ΨMP adduct: The structure of 
ΨMP glycosidase cocrystallized with R5P and uracil shows ring-opened ribose ΨMP 
covalently attached to Lys166.
61 
Ring opening and closing are correlated with an
approximately 90° rotation and a 2 Å shift of the uracil (Figure 2.5 A, B), thus 
occupying a binding site different from that of the K166A−ΨMP complex (Figure 2.7). 
In this binding site, O2 forms a hydrogen bond with Asn289. The ring-opened ribose 
retains hydrogen bonds between the 2′-hydroxyl group and Glu31 and between the 3′-
hydroxyl group and Asp149; however, the hydrogen bond to O3′ requires a rotation of 
the Glu31 carboxylate about the Cγ−Cδ bond compared to the ΨMP complex (Figure 
2.6). The phosphate group forms hydrogen bonds with Lys93, Ser147, W1, W2, and 
W7−W11. The water molecules near the uracil are not well defined, possibly because of 
the lower resolution (2.5 Å) of this structure. 
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Figure 2.5: Comparison of the ΨMP glycosidase complexes.61  
[(A) Stereoview of the K166A−ΨMP complex (B) Stereoview of the ΨMP 
glycosidase−ring-opened ribose ΨMP adduct (C) Stereoview of the ΨMP 
glycosidase−R5P adduct. Protein carbon atoms are colored green; ligand carbon atoms 
are colored yellow.] 
18 
Structure of the ΨMP glycosidase−ribose-5-phosphate (R5P) adduct: Crystals of ΨMP 
treated with R5P show a structure in which the R5P is in the ring-opened form and is 
covalently attached to Lys166 via an imine.
61
 The R5P superimposes closely with the
ring-opened ribose in the ΨMP adduct and forms hydrogen bonds between the 2-
hydroxyl group and Glu31 and between the 3-hydroxyl group and Asp149 (Figure 2.5 B, 
C). The phosphate binding site is essentially the same as for the previous complex. 
Water molecules in the uracil binding site are less ordered and more variable from 
protomer to protomer compared to those of the K166A−ΨMP complex (Figure 2.6). 
ΨMP glycosidase active site: The active site, as defined by the structure of the 
K166A−ΨMP complex, is located in a cleft formed by helices α12 and α13 and the loops 
following strands β2, β7, and β8 (Figure 2.6 A, B).61 The ΨMP ribose is in a C3′-endo
conformation; the glycosidic torsion angle is anti, and the C4′−C5′ bond is in a gauche, 
trans conformation. Including the Mn (II) coordination sphere, the active site contains 19 
well-ordered water molecules that are present in all three protomers. ΨMP is surrounded 
by 15 of the water molecules, and these mediate many of the active site contacts with the 
protein. One of the ΨMP phosphate oxygen atoms forms hydrogen bonds with W1 from 
the Mn (II) coordination sphere, Lys93, and water molecule W11 (Figure 2.6). 
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Figure 2.6: ΨMP glycosidase active site.61 
[(A) Stereoview of the K166A−ΨMP active site: ΨMP was observed in the active site 
upon cocrystallization of K166A with either ΨMP or R5P and uracil. ΨMP and Mn (II) 
form extensive hydrogen bond connections with the active site residues and water 
molecules. Interactions are shown by a network of dashed lines (B) Schematic diagram 
of the K166A−ΨMP complex.] 
 
 
A second phosphate oxygen atom forms hydrogen bonds with W2 from the Mn(II) 
coordination sphere, Ser147, and water molecule W10. The third phosphate oxygen 
atom forms hydrogen bonds with three water molecules (W7−W9), which interact 
through multiple contacts with the protein (Ser95, Thr112, Ala148 NH, Asp149, and 
Glu179*). The ribose O2′-hydroxyl group hydrogen bonds to Glu31; the O3′-hydroxyl 
group hydrogen bonds to Asp149 and the Val113 amide group, while O4′ hydrogen 
bonds with water molecule W12, which in turn hydrogen bonds to Lys93 and W19. The 
ΨMP uracil forms no direct hydrogen bonds with protein residues; however, N1, O2, 
N3, and O4 form hydrogen bonds with five water molecules. One water molecule (W14) 
20 
hydrogen bonds to N1 and W15 and forms a bridge to the ΨMP phosphate through two 
additional water molecules (W10 and W13).The second water molecule (W16) hydrogen 
bonds to O2, the side chain of Asn289, W17, and W18, which is positioned over the 
center of the uracil ring and hydrogen bonds to the amide nitrogen and carbonyl oxygen 
atoms of Gly132. The third water molecule (W15) also hydrogen bonds to O2, the amide 
nitrogen atom of Ala166, and W14. The fourth water molecule (W18) hydrogen bonds to 
N3, the carbonyl oxygen atom of Gly38, and the side chain of Asn289. The fifth water 
molecule (W19) hydrogen bonds to O4, the carbonyl oxygen atom of His37, and an 
additional water molecule (W12), which hydrogen bonds to O4′ of ΨMP and Lys93.61
Detection of a Lys166- R5P covalent adduct by mass spectrometry: To confirm the 
findings from the structural study, biochemical experiments were carried out on YeiN. 
The protein-substrate covalent adduct formation is investigated by intact protein mass 
spectrometry. The mass of wild-type ΨMP glycosidase was determined to be 35453.4 
Da by ICR-MS analysis (Figure 2.8A).
61
The mass of the reduced R5P complex was
35668.4 Da, corresponding to a mass increase of 215 Da (Figure 2.8A). This is 
consistent with a doubly protonated reduced R5P-derived imine of mass 214 Da due to 
the adduct formation with lysine 166 (Figure 2.7). Adduct formation was not observed 
when only uracil was incubated with ΨMP glycosidase (Figure 2.8A). 
21 
Figure 2.7: Predicted mass of the YeiN-R5P adduct 
The site of imine formation was identified by trypsin digestion of the reduced ΨMP 
glycosidase R5P adduct (Figure 2.8B−E).61Trypsin is a protease that cleaves after lysine
and arginine residues, and lysine modification blocks the cleavage reaction as trypsin 
cannot recognize the modified site. Trypsin digestion of the unmodified enzyme yielded 
the GAEHTFDISADLQELANTNVTVVCAGAK peptide (mass of 2930.4079 Da, 
amino acids 139−166). For ΨMP glycosidase incubated with R5P, trypsin digestion 
didn’t cut at the usual K166 residue but rather cut at the next lysine, K191 yielding the 
GAEHTFDISADLQELANTNVTVVCAGAKSILDLGLTTEYLETFGVPLIGYQTK 
peptide (mass of 5896.8759 Da, amino acids 139−191). This demonstrates that Lys166 is 
the R5P-modified residue. This was confirmed by similar ICR-MS analysis of the 
K166A mutant for which no mass increase was observed for the R5P-treated sample 
(Figure 2.8A). 
 22 
 
 
 
Figure 2.8: Analysis of the YeiN-R5P adduct by mass spectrometry.
61 
[(A) ICR-MS data for the identification of the borohydride-reduced ΨMP 
glycosidase−R5P adduct: The observed 179 Da adduct corresponds to enzyme 
gluconoylation. (B) MS chromatograms of the control sample. The black trace 
corresponds to data for the unmodified peptide, while the red trace corresponds to data 
for the R5P-bound peptide, which is not seen in the ΨMP glycosidase control. (C) Triply 
charged state of the unmodified peptide in the control ΨMP glycosidase sample. (D) MS 
chromatograms of the reduced ΨMP glycosidase−/R5P adduct. The pink trace 
corresponds to data for the unmodified peptide, while the green trace corresponds to data 
for the R5P-bound modified peptide. (E) Quadruply charged state of the R5P-bound 
modified peptide in the reduced ΨMP glycosidase−R5P adduct.] 
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Steady state kinetics parameters of ΨMP glycosidase and its mutants: Steady state 
kinetic parameters were determined by measuring the production of ΨMP during the 
reverse reaction while varying the uracil concentration at a saturating R5P concentration 
(Figure 1.5). Michaelis−Menten analysis (Figure 2.9) of the native enzyme indicated a 
Km value of 170 µM for uracil and a kcat of 3.74 s
−1
.
61
This corresponds to a catalytic
efficiency, kcat/Km, of 22 × 103 M
−1
 s
−1
. Steady state kinetic parameters were also
determined for the active site mutants E31A, K93A, K166A, and N289A (Table 1 and 
Figure A5 of Appendix A). The activity of D149A was below the detection limit even at 
an enzyme concentration as high as 100 µM and no activity was detected after several 
attempts (written as ND in Table 2.1). K93A has a higher Km value than the wild-type 
enzyme. E31A, K93A, K166A, and N289A have significantly lower kcat values, with 
E31A and K166A showing the largest effects. 
Figure 2.9: Michaelis-Menten plot for the ΨMP glycosidase.61 
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Table 2.1: Steady state kinetic parameters for the ΨMP glycosidase and mutants.61 
Enzyme kcat (s
-1
) Km (µM) kcat/Km (M
−1
 s
−1
) 
YeiN 3.74 ± 0.14 170 ± 22 (22 ± 4) x 10
3
 
K166A 0.0013 ± 0.0001 163 ± 23 8.0 ± 1.5 
E31A 0.0005 ± 0.0001 191 ± 39 2.6 ± 0.8 
K93A 0.23 ± 0.01 214 ± 18 (1.1 ± 0.1) x 10
3
 
N289A 0.22 ± 0.01 300 ± 22 (7.3 ± 0.8) x 10
2
 
D149A ND ND ND 
 
 
Pre-steady state kinetics analysis of ΨMP glycosidase reaction: In a rapid quench 
experiment, burst phase was observed for the ΨMP glycosidase catalyzed reaction 
indicating that the formation of product is much faster than product release step. The plot 
of turn over number vs. time(s) is shown in Figure 2.10. The data was fitted into the 
equation shown in the graph and from this equation; the burst amplitude (m2), burst rate 
(m3) and linear rate (m1) were determined to be 0.7±0.03, 124±14 s
-1
 and 1.01±0.11 s
-1
 
respectively (Table 2.2). 
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Figure 2.10: Pre-steady state kinetics for the ΨMP glycosidase. 
 
Table 2.2: Pre steady state kinetics parameters for the ΨMP glycosidase 
 
m1 1.01 ± 0.11 
m2 0.70 ± 0.03 
m3 124  ± 14 
 
 
Mechanistic implications: The mechanism of pseudouridine synthase has been 
extensively studied and is outlined in Figure 1.3.
30
The microscopic reverse of this 
reaction would seem to be a reasonable starting hypothesis for the reaction catalyzed by 
y = (m
1
* x) + m
2
 * [1- exp (-m
3
*x)] 
26 
ΨMP glycosidase (Figure 2.1). Our structural studies identified four snapshots of the E. 
coli ΨMP glycosidase reaction coordinate.61 Wild-type E. coli ΨMP glycosidase showed
the unliganded state, although a sulfate ion from the crystallization solutions occupied 
the phosphate binding site. Incubation of the K166A mutant with R5P and uracil resulted 
in a structure with the substrate ΨMP bound in the active site. Native ΨMP glycosidase 
incubated with R5P and uracil showed an intermediate in which ring-opened ribose 
ΨMP is covalently attached to Lys166. Finally, ΨMP glycosidase incubated with R5P 
alone resulted in a structure with ring opened R5P attached to Lys166. The structural 
studies suggested that the reaction involves an intermediate imine with Lys166. This was 
confirmed by mass spectrometry of the wild type enzyme and trypsin digested 
fragments. Kinetic studies of active site mutants suggested roles for individual amino 
acid active site residues. Comparison of the ΨMP glycosidase structures 60, 61 suggested
a role for conformational changes in ΨMP cleavage and product release. This series of 
experiments demonstrated that the ΨMP glycosidase-catalyzed reaction occurs by a 
mechanism that is significantly different from the microscopic reverse of the 
pseudouridine synthase mechanism.
30 
An alternative mechanistic proposal is outlined in Figure 2.11. Ring opening of the ΨMP 
ribose gives 21. This reaction requires acid−base catalysis. As no amino acids are 
apparent in the structure for this role (Figure 2.1), the ring-opening reaction probably 
occurs by a water-mediated protonation−deprotonation reaction. The conformation of 
the C glycosidic bond is reasonable for a concerted process (the C6−C5−C1−O4a 
27 
dihedral angle is 50°, while the optimal angle would be 90°). Related ribose ring-
opening reactions are catalyzed by GTP cyclohydrolase.
62
 Following ribose ring
opening, Lys166 undergoes a conjugate addition to the C−C double bond of 21 to give 
22 with the proton coming from Glu31. Subsequent cleavage of the C−C glycosidic 
bond by a retroaldol-type reaction releases the uracil anion, which is stabilized by 
hydrogen bonding of N1 to the hydroxyl of Thr130 and the amide NH of Gly131 and 
Gly132. Surprisingly, there are no stabilizing hydrogen bonds to the C2 or C4 carbonyl 
oxygen atoms of uracil. Hydrolysis of imine 19 gives 23, which will then cyclize to 10. 
In addition to the structures, the covalent linkage between Lys166 and the substrate is 
supported by the characterization of the R5P Lys166 imine by mass spectrometry. 
Figure 2.11: Mechanistic proposal for the ΨMP glycosidase.61 
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An alternative mechanism in which Lys166 displaces the pyrimidine from the ribose, as 
found, for example, in 8-oxoguanine DNA glycosylase
63
 is unlikely. Lysine 166,
modeled into the structure of the enzyme ΨMP complex, is not suitably positioned for 
direct base displacement, and the structure of the ring-opened ribose ΨMP complex is 
not consistent with this mechanism. The structure of UrdGT2, with the substrates 
modeled into the active site, suggests that this C−C glycosyl transferase does not use an 
imine intermediate.
58 
In this regard; our analysis suggests that ΨMP glycosidase may use
a new glycosidase mechanism.
61 
Implications from the steady state kinetics parameters: This mechanistic proposal 
allows us to suggest testable functions for the active site residues.
61
 Lys166 plays a key
role in facilitating the C glycosyl bond cleavage reaction, and as expected, the kcat value 
of the K166A mutant is 2900-fold lower than that of the wild type, with almost no 
change in Km. It is interesting that low levels of catalytic activity are observed for this 
mutant, suggesting that water can replace lysine in the mutant. Glu31 is likely to be the 
proton source for the lysine conjugate addition reaction (9 to 21 in Figure 19). Consistent 
with this role, the kcat value of the E31A mutant is 7500-fold lower than that of the wild 
type, with little change in Km. Lys93 contributes one of several interactions involved in 
phosphate binding. The kcat value of the K93A mutant is 17-fold lower than that of the 
wild type, with only a modest increase in Km. Asn289 hydrogen bonds to two water 
molecules that are in turn hydrogen bonded to the C2 carbonyl and to N3. These 
interactions stabilize the negative charge on the uracil in the conversion of 22 to 19 and 
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11. Consequently, the kcat value of the N289A mutant is 17-fold lower than that of the
wild type, with a small increase in Km. Asp149 forms a hydrogen bond to the substrate 
C3′ alcohol. We would therefore expect that the activity of the D149A mutant would be 
comparable to that of the wild type, which is inconsistent with our finding that it shows 
no detectable activity. One possibility is that the D149A mutant has misfolded; however, 
CD spectra of the wild type and D149A are nearly identical (unpublished data). Another 
possibility is that Asp149 serves indirectly as an acid and/or base through a charged 
network. We could not get any activity for this mutant under standard assay conditions.
61 
NMR analysis of the ΨMP glycosidase reaction mixture: Besides these biochemical 
studies, attempts have also been made to trap and identify the proposed intermediates 
using NMR spectroscopy (data not shown). Reactions were performed using both wild 
type ΨMP glycosidase (YeiN) and K166A mutant and 13C labeled substrates (13C1
ribose-5 phosphate and 
13
C4, 5 -uracil) and Mg
2+
 (as the reaction is slower than with
Mn
2+
) and were quenched at various time points by heating at 100
°
C for few minutes and
analyzed by NMR spectroscopy. Reactions were also monitored in real time scale by 
using NMR (added enzyme in the NMR tube carrying all other components and 
monitored after every 5 min). However, all our attempts to trap intermediates 
biochemically (compounds 21 and 22 as proposed in the mechanism, Figure 2.11) were 
unsuccessful as reaction always resulted in the formation of the final product 
pseudouridine monophosphate, 9. This suggested that probably these intermediates are 
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not released from the enzyme active site during the catalytic cycle or may be present in 
very low concentration in the solution to be detected by NMR spectroscopy. 
 
Role of the hydrated metal binding site: From the structural studies
61
, it was clear that 
ΨMP glycosidase contain heavily hydrated, octahedrally coordinated Mn (II) ions in 
which the ligands are an aspartate side chain and five water molecules. In addition, the 
water molecules in the second sphere (W6−W9) are also present in both structures, and 
all side chains in the second sphere are conserved, including Glu176 and Glu179 from 
the neighboring protomer. This heavily hydrated metal binding site is unusual and likely 
plays a role in anchoring the ΨMP phosphate. Two phosphate oxygen atoms form 
hydrogen bonds to W1 and W2, which are in the Mn (II) coordination sphere. The 
phosphate group also hydrogen bonds to Ser147 and Lys93, which are conserved in both 
structures. While the ribose and uracil both undergo movement during catalysis, the 
phosphate remains in the same position, with no hydrogen bonding changes. ΨMP 
glycosidase shows the highest activities with Fe(II), Co(II), and Mn(II), while Zn(II) 
and, to a lesser extent, Ni(II) were inhibitory.
37
 These observations suggest that the ionic 
radius of the metal ion may play a role in properly positioning the substrate. 
 
Role of conformational changes in catalysis: Both the protein and substrate undergo 
conformational changes during catalysis. The uracil undergoes a 90° rotation and a 2 Å 
shift after ring opening and Lys166 adduct formation.
61
 In the glycosidase ΨMP 
complex, uracil forms no hydrogen bonds with protein atoms; however, after shifting 
31 
position, uracil hydrogen bonds through O2 to Asn289, which is located at the opposite 
end of the active site relative to the phosphate. Repositioning of the uracil also places N1 
near the amide nitrogen atoms of Gly131 and Gly132, which are absolutely conserved. 
Heavy reliance in the binding site on water mediated interactions is consistent with the 
need for major repositioning of an intermediate during catalysis. 
Conclusion 
The ΨMP glycosidase complexes described here give four snapshots of the reaction 
coordinate and provide key structural insights into the enzymatic hydrolysis of C-
glycosides. The mass spectrometric studies and the steady state kinetics analysis of the 
ΨMP glycosidase and the active site mutants also provide substantial evidence in 
support of the structural data. Most of the characterized glycosidases utilize a 
dissociative mechanism to reversibly cleave C−N and C−O glycosidic bonds. During 
such a mechanism, the opening of the ribose ring was not observed and there is no 
requirement for metal ion cofactors.  In contrast, the structural and biochemical studies 
reported here demonstrate that ΨMP glycosidase requires divalent metal ions (such as 
Mn
2+
 or Co
2+
) and utilizes a new mechanism involving ribose ring opening and
subsequent covalent linkage between C1′ and an active site lysine, thus setting the stage 
for a facile C glycosyl bond fragmentation by a novel retro aldol type reaction 
mechanism. To the best of our knowledge, this is the first mechanistically characterized 
example of a C- glycosidase. 
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Experimental procedures 
Chemical reagents: R5P and uracil were purchased from Sigma-Aldrich. Tris(2-
carboxyethyl)phosphine (TCEP) was purchased from Hampton Research. Kanamycin 
and IPTG were purchased from Fischer Scintific. Ni-NTA resin was obtained from 
Qiagen (Valencia, CA). 
Cloning, overexpression and purification of ΨMP glycosidase: Standard methods were 
used for DNA restriction endonuclease digestion, ligation, and transformation of 
DNA.
62-64
. Plasmid DNA was purified with a GeneJet miniprep kit (Fermentas, Glen
Burnei, MD). DNA fragments were separated by agarose gel electrophoresis, excised, 
and purified with the Zymoclean gel DNA recovery kit (Zymo Research, Orange, CA). 
E. coli strain MachI (Invitrogen, Madison, WI) was used as the recipient for 
transformations during plasmid construction and for plasmid propagation and storage. 
An Eppendorf Mastercycler and Phusion DNA polymerase (New England Biolabs, 
Ipswich, MA) were used for polymerase chain reaction (PCR). All restriction 
endonucleases and T4 DNA ligase were purchased from New England Biolabs. E. coli 
strain BL21 (DE3) and the pET overexpression systems were purchased from Novagen 
(Madison, WI). The yeiN gene was amplified via PCR from E. coli K12 genomic DNA 
using the following primers: upstream primer 5′-GGG TAG CAT ATG TCT GAA TTA 
AAA ATT TCC CCT G-3′ (inserts an NdeI site at the start codon of the yeiN open 
reading frame) and downstream primer 5′-CCC TAC TCG AGT TAA CCC GCG AGA 
CGC TGA TAT TC-3′ (inserts an XhoI site after the end of the yeiN open reading 
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frame). The purified PCR product was digested with NdeI and XhoI, purified, and ligated 
into similarly digested pTHT, a pET-28-derived vector, which allows attachment of a 
modified six histidine tag followed by a tobacco etch virus protease (TEV-protease) 
cleavage site onto the N-terminus of the expressed protein. Colonies were screened for 
the presence of the insert, and a representative plasmid was designated pEcYeiN.THT. 
The PCR-derived DNA was sequenced and shown to contain no errors. 
The yeiN gene was further transformed into E. coli strain BL21 (DE3) (Novagen). The 
cells were grown overnight in a 10 mL starter culture in Luria-Bertani (LB) medium
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containing 30 μg/mL kanamycin, then transferred to cultures containing 1.5 L of LB 
medium, and incubated at 37 °C while being shaken until an OD600 of 0.8 was 
achieved. The culture was then induced with 1 mM isopropyl 1-β-D-galactopyranoside 
(IPTG) and incubated overnight at 15 °C. Cells were harvested by centrifugation at 
10000g for 30 min at 4 °C, resuspended in lysis buffer containing 50 mM 
tris(hydroxymethyl)-aminomethane (Tris) (pH 8.0) 300 mM NaCl, and 10 mM 
imidazole, and lysed by sonication. The lysate was centrifuged at 40000g for 30 min, 
and the supernatant was loaded onto a column containing 5 mL of Ni-NTA resin 
(Qiagen) preequilibrated with lysis buffer. The column was then washed with 3 times the 
volume of wash buffer containing 50 mM Tris (pH 8.0), 300 mM NaCl, and 30 mM 
imidazole for 1.5 h. The protein was eluted with 50 mM Tris (pH 8.0), 300 mM NaCl, 
and 250 mM imidazole. The eluted protein was then subjected to size exclusion 
chromatography using an ACTA Explorer fast performance liquid chromatography 
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system with a HiLoad 26/60 Superdex 200 prep grade column (GE Healthcare). The 
resulting protein was more than 95% pure as judged by sodium dodecyl 
sulfate−polyacrylamide gel electrophoresis analysis (unpublished experiments). The 
protein was then concentrated to 15 mg/mL using an Amicon concentrator (30 kDa 
molecular mass cutoff filter, Millipore), flash-frozen, and stored at −80 °C. 
ΨMP glycosidase mutagenesis: Site-directed mutagenesis was performed by a standard 
PCR protocol using PfuUltraII DNA polymerase per the manufacturer’s instructions 
(Agilent) and DpnI to digest the methylated parental DNA prior to transformation. In 
addition to the forward and reverse primers required to introduce the mutation, a third 
primer was designed to screen for the presence of the mutation by colony PCR (Table 1 
Appendix A). For screening, the primers designated “sF” were paired with the T7T 
primer (5′-GCTAGTTATTGCTCAGCGG-3′) and the primers designated “sR” were 
screened with the T7Plac primer (5′-TATAGGGGAATTGTGAGCGG-3′). All the 
mutants were verified by sequencing. 
Enzymatic synthesis of ΨMP: ΨMP glycosidase (2.5 mg), uracil (100 mM), and R5P 
were incubated in a buffer containing 0.5 mM MnCl2 and 25 mM HEPES (pH 7.1) at 
25°C for 1 h. The enzyme was removed using an Amicon 30 kDa molecular mass cutoff 
(Millipore) filter. The reaction product was identified as ΨMP by co-migration with an 
authentic sample of ΨMP during high-performance liquid chromatography (HPLC) 
analysis as well as MS and NMR analysis. 
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Crystallization of the ΨMP glycosidase61: ΨMP glycosidase was crystallized using the 
hanging drop vapor diffusion method at 22 °C. The initial crystallization condition was 
determined using sparse matrix screens Crystal Screen 1 and 2 (Hampton Research). The 
optimized reservoir conditions included 20% polyethylene glycol 4000, 0.2 M sodium 
acetate, and 0.1 M Tris (pH 7.0). ΨMP glycosidase was incubated with 4 mM MnSO4 
before crystallization. The drops contained 1.5 μL of a protein solution and 1.5 μL of a 
reservoir solution. Prismatic crystals grew within 2 days to a size of 200 μm × 50 μm × 
50 μm. The ΨMP glycosidase−R5P complex was cocrystallized under similar conditions 
except that the protein was incubated with 4 mM MnCl2 and 2 mM R5P for 30 min prior 
to crystallization. The ΨMP glycosidase−ring-opened ribose ΨMP complex was 
obtained by cocrystallizing ΨMP glycosidase with 4 mM MnCl2, 2 mM R5P, and 
saturated uracil. The K166A−ΨMP complex was prepared by cocrystallizing the mutant 
enzyme with R5P and uracil (by Siyu Huang, Ealick lab, Cornell University). 
Data collection and processing: Prior to data collection, crystals were soaked in a 
cryoprotectant solution of 5% glycerol in mother liquor to avoid damage during 
vitrification. Data sets for ΨMP glycosidase and the complexes were collected at 
Northeast Collaborative Access Team (NE-CAT) beamline 24- ID-C at the Advanced 
Photon Source (APS) using an ADSC Quantum 315 detector (Area Detector Systems 
Corp.) at a wavelength of 0.9795 Å with 1 s exposure times and 1° oscillation angles. 
The data set for the K166A−ΨMP complex was collected at Cornell High Energy 
Synchrotron Source (CHESS) using an ADSC Quantum 270 detector at a wavelength of 
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0.9180 Å with 1 s exposure times and 1° oscillation angles. The detector distances were 
275, 350, 325, and 200 cm for the ΨMP glycosidase, the R5P complex, the ring-opened 
ribose ΨMP complex, and the K166A−ΨMP complex, respectively. Data were indexed, 
integrated, and scaled using the HKL2000 program suite.
66
 Data collection statistics are
reported
61
 (by Siyu Huang, Ealick lab, Cornell University).
Structure determination and refinement: The structure of E.coli ΨMP glycosidase was 
determined by molecular replacement using MOLREP.
67
 The search model was a
monomer of Protein Data Bank (PDB) entry 1VKM, which has a sequence 39% 
identical to that of ΨMP glycosidase, after modification by CHAINSAW.68 1VKM was
originally reported to be an indigoidine (IndA)-like protein from Thermotoga maritima
60
but later was shown to be a ΨMP glycosidase.37 The model was refined through
successive rounds of manual model building using COOT
69
 and restrained refinement
with REFMAC5.
70
 Water molecules were then included after the model converged,
followed by two additional rounds of refinement. The structure of the ΨMP 
glycosidase−ringopened R5P adduct was determined by using the structure of 
unliganded ΨMP glycosidase as the model and refining with PHENIX.71 The structure
of the ΨMP glycosidase−ringopened ribose ΨMP adduct, which crystallized in a 
different space group, was determined by molecular replacement using MOLREP
67 
using
a monomer from the refined ΨMP glycosidase as the search model. The structure of the 
K166A−ΨMP complex was determined by using the structure of the ΨMP 
glycosidase−ring-opened ribose ΨMP adduct as the model and refining with PHENIX.71
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The ligand contents and alternative side chain conformations were determined by Fobs − 
Fcal maps and composite omit maps from PHENIX.
71
 All ligands were clearly observed 
in the composite omit map but were not placed until the last stage of the refinement. The 
final refinement statistics are reported
61
 (by Siyu Huang, Cornell University). 
 
Comparison with other protein structures: A structural similarity search for ΨMP 
glycosidase was performed using DALI.
72
 Not surprisingly, PDB entry 1VKM, which 
was used as the search model during molecular replacement, showed the highest degree 
of similarity with a Z score of 42.2 (39% identical sequence)
61
 (by Siyu Huang, Ealick 
lab, Cornell University). 
 
HLPC analysis of the ΨMP glycosidase reaction mixture: HPLC analysis following a 
linear gradient, at a flow rate of 1 mL/min, was used with absorbance detection at 254 
nm. Solvent A was water; solvent B was 100 mM K2HPO4 (pH 6.6), and solvent C was 
methanol: 100% B at 0 min, 10% A and 90% B at 5 min, 25% A, 60% B, and 15% C at 
7 min, 25% A, 60% B, and 15% C at 17min, 30% A, 40% B, and 30% C at 19 min, 
100% B at 21 min, and 100% B at 30 min. The column used was a Supelcosil LC-18-T 
HPLC column (15 cm × 4.6 mm, 3 μm particle size). 
 
Determination of kinetics parameters for the ΨMP glycosidase reaction: Uracil 
concentrations were varied while the R5P concentration was kept at saturation (1 mM) 
and the Mn (II) concentration at 250 μM. ΨMP formation was monitored by HPLC 
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analysis. Each reaction mixture was divided into 90 μL aliquots, and 10 μL of 10 μM 
ΨMP glycosidase was added to achieve the final concentration of 1μM. For each set of 
reactions, the reaction was quenched at 20s, 40 s, 1 min, 2 min, 3 min, 5 min, and 10 min 
time points when the mixture was heated at 100 °C for 2 min. In the case of K166A, the 
uracil concentrations were varied while the R5P concentration was kept at 1 mM and the 
Mn(II) concentration at 250 μM for five different sets of reactions. Each reaction 
mixture was divided into 85 μL aliquots, and 15 μL of 250 μM K166A was added to 
start the reaction (final concentration of 37.5 μM). For each set of reactions, the reaction 
was quenched at 20 s, 40 s, 1 min, 2 min, 3 min, 5 min, and 10 min time points when the 
mixture was heated at 100 °C for 2 min. All samples were analyzed by HPLC, and the 
amount of ΨMP formed was plotted against time for each set of substrate concentrations. 
The initial slopes from each set of reactions were then plotted against the substrate 
concentration and fit to the Michaelis−Menten equation using KaleidaGraph (Synergy 
Software). The mutant E31A, K93A, H137A, D149A, and N289A activities were 
measured using a similar procedure (Figure A5, Appendix A). 
 
Biochemical characterization of the ΨMP glycosidase-R5P adduct: A reaction mixture 
containing 2 mM R5P and 1 mM Mn(II) in 50 mM Tris-HCl, 100 mM NaCl, and 2 mM 
TCEP (pH 8.0) was incubated at room temperature for 1 h with ΨMP glycosidase (50 
μM), followed by addition of sodium borohydride (2 mg) and further incubation at room 
temperature for 45 min. The sample was then buffer-exchanged into 10 mM ammonium 
acetate (pH 8.0) using a Bio-Rad desalting column and analyzed by ICR-MS. Control 
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samples, one containing 2 mM uracil and the other lacking R5P and Mn(II), were 
similarly prepared and analyzed. A similar experiment was also performed on the 
K166A mutant of the enzyme. To locate the site of adduct formation; trypsin digestion 
analysis was performed on each of these samples as follows. Ten microliters of 
guanidine hydrochloride (6 M) was added to each sample (50 μL containing 100 μg of 
ΨMP glycosidase), followed by 1 μL of DTT (200 mM). After 1 h incubation at room 
temperature, 10 μL of iodoacetamide (200 mM) was added, and the reaction mixture was 
further incubated in the dark for 1 h. Twenty-nine microliters of ammonium bicarbonate 
buffer was further added to reduce the final concentration of guanidine hydrochloride to 
0.6 M (final volume of 100 μL). One microliter of trypsin in 50 mM ammonium 
bicarbonate buffer (pH 8.0, 1 μg/ μL) was added, and the samples were incubated at 37 
°C for 20 h. The samples were then analyzed by LC-MS.
61,73 
 
Rapid quench experiment for the ѰMP glycosidase reaction: The reaction mixture 
containing YeiN (500 µM) preincubated with ribose 5-phosphate (1.5mM) and Mn
2+
 
(1.5 mM) in syringe A was reacted with Uracil (500µM) present in syringe B in the 
KinTeK rapid quench apparatus. The reaction was quenched using 5M HCl at various 
time points and quenched reaction mixtures were collected. The reaction samples were 
neutralized by 5M potassium phosphate buffer (pH ~10) to pH 6.5 and were analyzed by 
HPLC. The amount of pseudouridine monophosphate formed per unit enzyme 
concentration was plotted against time to determine the pre steady state kinetics 
parameters. 
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CHAPTER III 
MENAQUINONES: STRUCTURE, FUNCTION AND BIOSYNTHESIS 
Introduction 
Menaquinones (MK) belong to a class of compounds known as isoprenoid quinones that 
are composed of a polar head group and hydrophobic side chain.
74, 75
 The non-polar
isoprenoid side chain gives the molecules a lipid-soluble character and anchors them in 
membrane lipid bilayers, whereas the hydrophilic head group enables interaction with 
hydrophilic parts of proteins in the polar interphase region of the membranes.
76, 77
A vast majority of biological isoprenoid quinones, which are also termed as 
prenylquinones, belong to either benzoquinones or naphthoquinones.
75
 The two most
important members of benzoquinones are ubiquinones (UQ) and plastoquinones (PQ); 
differing in the pattern of ring substitution, chain length of the isoprenoid side chain, 
degree of saturation as well as in the presence of additional groups (Figure 3.1). Some of 
the important naphthoquinones include menaquinones (MK, vitamin K2), 
demethylmenaquinones (DMK) and phylloquinones (PhQ, vitamin K1) (Figure 3.1). 
They are represented as Q-n or MK-n, where n refers to a side chain composed of 
varying numbers of five carbon isoprenoid residues and the number of such units is 
indicated.
78
 Thus, Q-8 and MK-8 indicate ubiquinone and menaquinone with side chains
of 40 carbon atoms, respectively. MK is considered as vitamin, while UQ is not, due to 
the fact that vitamin K is an essential nutrient (cannot be synthesized) in mammals, 
whereas UQ can be synthesized from tyrosine and hence it is not an essential nutrient. 
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Prokaryotes contain isoprenoid quinones of both kinds in varying amounts. Most aerobic 
Gram-negative bacteria contain Q as the sole quinone, while the aerobic Gram-positive 
bacteria contain MK as the only quinone. Most of the anaerobic bacteria, irrespective of 
Gram-positive or negative, contain MK as their sole quinone. However, Gram-negative 
facultative anaerobes such as E.coli contain both Q and MK (mainly UQ-8, MK-8 and 
DMK-8), and hence they are able to grow under both aerobic and anaerobic 
conditions.
74, 75
 Structures of some isoprenoid quinones are shown in Figure 3.1 
(Benzoquinones include: ubiquinone (UQ-8), 24 and plastoquinone (PQ-9), 25; 
naphthoquiones include: menaquinone (MK-8), 26, demethylmenaquinone (DMK-8), 27 
and phylloquinone (PhQ), 28).  
 
 
 
Figure 3.1: Structures of isoprenoid quinones. 
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The isoprenoid quinones are obligatory components of the electron transport chain in 
prokaryotes.  The quinone ring can undergo two-step reversible reduction leading to the 
more polar quinol form which is thought to preferentially localize in polar, interphase 
region of membranes
77
 (Figure 3.2). This ability of reversible reduction and the presence 
of the lipid-soluble side chain make them ideal candidates for their function as hydrogen 
shuttles between different protein complexes of biological membranes. Figure 3.2 shows 
the redox reactions of the quinone ring in which Q (29) is the oxidized form, Q
-.
 (30) is 
the charged semiquinone radical which is unstable but can be stabilized by interaction 
with proteins and QH2 (31) is the stable non charged hydroquinone or quinol form. 
 
 
Figure 3.2: Redox reactions of the quinone ring.  
 
They function as membrane-bound, mobile hydrogen carriers but some of these 
molecules are permanently associated with proteins and participate in electron transport 
within protein complexes. In E.coli, under anaerobic conditions, when nitrate is the 
electron acceptor, UQ is the preferred quinone, however, MK can substitute in the 
absence of UQ.
79
 But when fumarate, trimethylamine N-oxide (TMAO) or 
dimethylsulfoxide (DMSO) serves as electron acceptors, under anaerobic conditions, the 
43 
presence of MK is essential.
80-82
 Moreover, the reduced forms of the isoprenoid quinones
have pronounced antioxidant properties and protect membranes from lipid peroxidation 
and deleterious effects of reactive oxygen species on membrane components.
75 
Menaquinones: Occurrence and Function
Menaquinones (MK) are the most widespread microbial respiratory quinones that can be 
found in many groups of archaea and bacteria such as different categories of 
proteobacteria, gram-positive bacteria, green sulfur bacteria, green filamentous bacteria, 
dienococci and flavobacteria.
83-86
 The isoprenoid side chain of menaquinones in these
organisms is most frequently composed of 6-10 prenyl units (often fully unsaturated), 
but also homologues with 1 to 14 prenyl units were also found.
74
In microorganisms, menaquinone is a lipid soluble molecule that has low midpoint redox 
potential and shuttle electrons between the membrane bound protein complexes/ redox 
enzymes in the electron-transport chain of the respiratory and photosynthetic systems. A 
representation of the bacterial respiratory chain is shown along with the enzymes that 
use MK during electron transfer (Figure 3.3).
87
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Figure 3.3: A pictorial representation of the bacterial electron transport chain.
87 
 
Many of the enzymes of the respiratory chain that use MK/MKH2 system are able to 
generate proton gradient, which is crucial for energy conserving processes. Proton 
gradient can be generated by two mechanisms: pumping the protons across the 
membranes and the so called redox loop mechanism, where the reduction of one 
substrate, accompanied by proton(s) binding, occurs on one side of the membrane, 
whereas oxidation of the other substrate, accompanied by proton(s) release, occurs on 
the opposite site, while electrons are transferred through the protein.
88, 75
 Some of the 
examples of bacterial respiratory enzymes
 
that use MK as a cofactor include succinate: 
quinone oxidoreductases,
89-92
, quinol: fumarate oxidoreductase,
93
 NADH: MK 
oxidoreductases
94
, hydrogenase
95
, thiosulfate reductase
96
,
 
formate dehydrogenase
97
, 
nitrate reductase
98,99
, , heme:copper oxidases
100
, cytochrome bc complexes
101
 and 
cytochrome bd complexes.
102 
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Menaquinones also participate in electron transfer chain in bacterial photosynthesis. 
MKs are found both in photosystem II (PS II)-type reaction centers of purple bacteria 
and green filamentous bacteria.
103,104
 They also occur in photosystem I (PS I)-type
reaction centers of green sulfur bacteria
105
 and heliobacteria.
103,106,107
They are also found
in high amounts in PS-I of certain cyanobacteria.
108 
Besides the function of MK in electron transfer, its participation in cellular signaling of 
Klebsiella pneumoniae was found, where MK takes part in regulation of nitrogen 
fixation. It was observed that NifL protein, acting as a corepressor in the regulation of 
expression of nitrogen fixation genes, can be reduced by MKH2 under anerobic 
conditions, followed by NifL sequestration on the cellular membrane.
109 
Vitamin K plays a specific physiological role in blood coagulation in mammals. It is an 
essential vitamin in humans and other mammals, where it functions as a co-substrate in 
the carboxylation of glutamic acid residues in proteins involved in blood clotting
110
 and
bone formation
111
. Under normal conditions, specific glutamate residues in the N-
terminal region of the proteins involved in blood coagulation and bone metabolism are 
carboxylated to γ-carboxyglutamates (Gla) with the help of vitamin K (Figure 3.4) 
which, in turn, activate them to bind Ca
2+
. Anti-clotting drugs such as warfarin targets
the enzyme vitamin K epoxide reductase (Figure 3.4) that converts vitamin K epoxide 
back to the active form of the cofactor.
112
 Vitamin K is also involved in calcium
metabolism, tissue calcification and cell cycle regulation.
113 
Vitamin K deficiency in
46 
humans
114, 115
 leads to the synthesis of abnormal forms of coagulation factors. Other
proteins in bone and dentin (such as Osteocalcin)
 111
, kidney and spermatozoa also
contain Gla. A major portion of human requirement for vitamin K is provided by the 
microflora of the gut. The rest is obtained from plant sources.
115, 116
 Figure 3.4 shows
Vitamin-K dependent carboxylation of glutamate (Glu) residues (32) of blood clotting 
factors by γ-glutamyl carboxylase with help of reduced form of vitamin K (33) forming 
γ-carboxyglutamate, Gla (34) and vitamin K epoxide 2, 3-epoxide (35). Gla helps in 
binding Ca
2+
 ions to initiate the blood clotting process. Anti-clotting drugs such as
warfarin (36) inhibit vitamin K epoxide reductase which converts 35 back to 33. 
Figure 3.4: Vitamin-K dependent carboxylation of glutamate (Glu) residues. 
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Biosynthesis of menaquinone 
During the biosynthesis of menaquinones (and other isoprenoid quinones), the head 
group precursor and the isoprenoid side chain are synthesized separately. Then both 
counterparts are condensed by an enzyme belonging to the prenyltransferase family, 
followed by further modifications on the resulting product.
75
 The primary precursors for 
the isoprenoid chain are dimethylallyl diphosphate (DMAP) and isopentenyl diphosphate 
(IPP). The isoprenoid side chain is formed from these precursors through series of 
condensation reactions carried out by a specific prenyl diphosphate synthase. There are 
two distinct pathways leading to the biosynthesis of these precursors: mevalonate 
(MVA) pathway and 1-deoxy-D-xylulose-5-phosphate (DXP) pathway and different 
taxonomic groups utilizes different pathway.
117
 For instance, majority of bacteria use 
DXP pathway (exceptions include Myxococcus fulvus which use MVA pathway and 
Streptomyces which possess both pathways), while archaea are believed to use the MVA 
pathway.
117
 All the animals and fungi take advantage of the MVA pathway 
117 
while 
higher plants use both of them.
118 
 
In prokaryotes, there are two different pathways for the biosynthesis of the 
naphthoquinone core (polar head group) of menaquinone (MK). Both pathways are 
branches of the shikimate pathway that diverge at chorismate and converge at DMK.
119, 
120
 The vast majority of bacteria produce MK by the well-established o-succinylbenzoate 
(OSB) pathway, which is also known as the classical pathway.
121, 122
 Recently an 
alternative pathway for producing menaquinone, termed as futalosine pathway,
123, 124
 
48 
was discovered in Streptomyces coelicolor which was later demonstrated in 
Helicobacter pylori, Campylobacter jejuni and Thermus thermophilus. Moreover, 
occurrence of this new pathway was confirmed in several Gram negatives and Archaea, 
mainly in chlamydia and spirochetes.
123
 This pathway is distributed only in prokaryotes
and absent in eukaryotes, including fungi and yeasts. However, till date, no 
microorganism is found that possesses both the classical and the alternative pathway.
123 
Classical pathway (o-succinylbenzoate pathway) 
Biosynthesis of MK by this pathway, studied in E.coli, has been elucidated on the basis 
of isotopic tracer experiments, isolation of mutants blocked in different steps, isolation 
and identification of accumulated intermediates in the mutants and by in-vitro assays 
using recombinant enzymes.
121, 122
 Results from the radioisotope tracer experiments led
to the conclusion that the naphthoquinone portion of MK arise from shikimate derived 
chorismate and 2-ketoglutarate while methyl and isoprenoid side chains are derived from 
S-adenosylmethionine (SAM) and an isoprenyl alcohol pyrophosphate ester respectively. 
The isotopic labelling pattern is summarized (Figure 3.5).
125-129 
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Figure 3.5: Primary biosynthetic precursors of MK in the classical pathway 
Subsequently, it was shown that the benzenoid aromatic compound, o-succinylbenzoate 
(OSB)
130
 and the naphthalenoid aromatic compound, 14-dihydroxy-2-naphthoate
(DHNA)
131
 were incorporated into the naphthoquinone ring of MK validating the
intermediacy of these compounds in the pathway (Figure 3.6). This result was confirmed 
by the demonstration that menB and menA mutants of E. coli excrete OSB and DHNA 
into the culture medium, respectively.
132 
Later on it was also shown that carbon one of
glutamate (2-ketoglutarate) was lost and consequently not incorporated to OSB or finally 
into MK
 
(Figure 3.6).
133 
In this classical pathway studied in E.coli in great detail, eight enzymes encoded by men 
genes 
120, 122, 
and the recently identified DHNA-CoA thioesterase
134
 are involved in MK
formation. In this pathway (Figure 3.6), chorismate, 39 which is derived from the 
shikimate pathway, is initially converted into isochorismate, 40 by the isochorismate 
synthase, MenF. In the next step, 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-
50 
caroxylate (SEPHCHC), 42 is formed from 40 and 2-ketoglutarate, 41 in the reaction 
catalyzed by MenD, which is a thiamin pyrophosphate (TPP) dependent enzyme. 
Figure 3.6: Classical pathway for the biosynthesis of menaquinone, 26 (MK-8) 
Thereafter, MenH catalyzes the conversion of 42 into 2-succinyl-6-hydroxy-2, 4-
cyclohexadiene-1-carboxylate (SHCHC), 43. This compound is dehydrated by MenC to 
give the first aromatic compound of the pathway, o-succinylbenzoate (OSB), 44. This is 
followed by its attachment with CoA yielding o-succinylbenzoyl-CoA, 45 in a reaction 
catalyzed by MenE. The latter is then converted into 1, 4-dihyroxy-2-naphthoyl-CoA, 46 
(DHNA-CoA), by MenB. It is then converted to 1,4-dihydroxy-2-naphthoate, 47 
(DHNA) by a recently discovered enzyme DHNA-CoA thioesterase.
134
 In the last two
51 
steps of the pathway, MK, 26 is synthesized by MenA and MenG, which catalyze 
prenylation (using octaprenyl pyrophosphate for MK-8) and S-adenoylmethionine 
(SAM) dependent methylation, respectively. The number of prenyl units in the attached 
isoprenoid side chain is determined by the length of isoprenoid pyrophosphate and may 
differ among species (e.g. E.coli- maily MK-8, Bacillus firmus-MK-7 etc.).
85
 The
majority of enzymes involved in MK synthesis are found to be soluble and mechanistic 
studies on each of these enzymes have been performed.
122
The MK and phylloquinone (vitamin K1) biosynthetic pathways are unique to bacteria 
and plants, respectively, and are absent in humans and animals. Hence, there is great 
research interest and opportunity to discover novel chemicals that will inhibit the 
enzymes of the pathway and could be used as herbicides and chemotherapeutic agents 
against human pathogens such as multidrug-resistant Mycobacterium tuberculosis and 
methicillin-resistant Staphylococcus aureus (MRSA). Several studies relating to 
discovery of inhibitors and antibiotic compounds targeting the enzymes on the 
menaquinone biosynthetic pathway have been reported.
87, 135-138 
Alternative pathway (futalosine pathway) 
Based on bioinformatics studies, it was found that some strains of Streptomyces such as 
S. coelicolor A3(2) and S. avermitilis do not possess the orthologs of the men genes of 
the classical E.coli pathway, except for two genes menA and menG, even though they 
synthesize MK.
123,139,140
 In addition to them, Epsilon and Delta categories of
52 
proteobacteria, including Helicobacter pylori and Campylobacter jejuni, which are 
known to cause gastric carcinoma and diarrhea, respectively, also lacked the men gene 
orthologues.
123
 These facts strongly suggested that the naphthoquinone moiety of MK is
synthesized via an alternative pathway in these bacteria. From the isotopic labeling 
studies done on Streptomyces sp., using 
13
C glucose, it was established that the A ring of
MK is derived from the shikimate pathway while the remaining carbons of the B ring are 
reported to be derived from phosphoenol pyruvate (PEP) and an unidentified metabolite 
derived from C-5 and C-6 carbons of glucose.
124
 The labelling pattern is shown in Figure
3.7. 
Figure 3.7: Labelling pattern in the alternative menaquinone biosynthetic pathway. 
Furthermore, based on the distinct labelling patterns and biochemical experiments, 1, 4-
dihydroxy-6-naphthoate was deduced as an intermediate of this pathway. Later on, based 
on in-vivo studies using MK auxotrophs, it was established that the branch point for this 
53 
pathway is also at chorismate derived from the shikimate pathway.
123
 Finally,
Tomoshige Hiratsuka et al were able to delineate the general outlines of an alternate 
menaquinone biosynthetic pathway in S. coelicolor A3(2) with the help of 
bioinformatics screening and various biochemical techniques such as gene knockouts, 
shotgun cloning with isolated mutants and in vitro studies with recombinant enzymes.
123, 
141, 142
In this alternative pathway (Figure 3.8), designated as the futlaosine pathway, 
futalosine, 49 is proposed to form from chorismate and presumably inosine, 48 and 
phosphoenolpyruvate (PEP), 38 in a complex reaction catalyzed by MqnA (SCO4506). 
Recently, 6-amino-6-deoxyfutalosine is also reported as the first intermediate of this 
pathway in C. jejuni and H. pylori
143
 in place of futalosine discovered in S.coelicolor.
Figure 3.8: Alternative pathway for menaquinone biosynthesis 
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In the next step, 49 is converted to dehypoxanthine futalosine (DHFL), 50 by futalosine 
hydrolase, MqnB (SCO4327)
144
, which is then transformed into cyclic dehypoxanthine
futalosine (CDHFL), 51 by the radical SAM enzyme MqnC (SCO4550)
143
. MqnD
(SCO4326) then converts 28 to 1, 4-dihydroxy-6-naphthoic acid, 52 which is an 
important intermediate on the pathway. In the later steps of the pathway, based on the 
annotation of the open reading frames of S. coelicolor A3(2), it was presumed that 
SCO4491 (prenylation), SCO4556 (methylation), SCO4490 (decarboxylation), and 
SCO4492 (decarboxylation) would be involved.
123
Research opportunity 
Discovery of this alternative pathway opened up new prospects in the investigation of 
some novel and intriguing enzymology involved. In vitro reconstitution using 
recombinant enzymes and in depth mechanistic studies on these enzymes are yet to be 
achieved. Moreover, since humans and commensal intestinal bacteria, such as 
lactobacilli, lack this pathway; hence it represents an attractive target for the 
development of chemotherapeutics against some human pathogens. Hence, like the 
classical pathway, this new pathway also represents a novel target for drug discovery, 
however, against some different pathogenic strains of bacteria.
123, 141
 So far, one study
has been reported in which an attempt has been made to find a suitable inhibitor for this 
pathway in H.pylori.
145
 Our aim was to investigate the in-vitro reconstitution of the first
step of this important menaquinone
146
 biosynthesis pathway and carry out mechanistic
studies on these enzymes. 
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CHAPTER IV 
MENAQUINONE BIOSYNTHESIS: RECONSTITUTION, MECHANISTIC AND 
STRUCTURAL STUDIES ON CHORISMATE DEHYDRATASE, MqnA
*# 
Introduction 
In the early steps of the alternative menaquinone biosynthesis pathway discovered in S. 
coelicolor A3(2),
123
 it was proposed that MqnA catalyzes the formation of futalosine
from chorismate, inosine and phosphoenolpyruvate using unknown chemistry (Figure 
4.1).
123,124
 However, attempts to reconstitute MqnA in vitro were unsuccessful.
123
 The
aim here was to reconstitute the activity of MqnA and verify the proposed step. 
Figure 4.1: Proposed precursors of futalosine in the alternative pathway. 
*Part of this chapter is reprinted with permission from “Menaquinone Biosynthesis: Formation
of Aminofutalosine Requires a Unique Radical SAM Enzyme” by Mahanta, N.; Fedoseyenko, 
D.; Dairi, T.; Begley, T. P., 2013. J. Am. Chem. Soc., 135, 15318-15321, Copyright [2013] by 
American Chemical Society. 
#
(Nilkamal Mahanta carried out all the biochemical studies. Dmytro Fedoseyenko  synthesized 
compound 53. Cynthia Kinsland, Ealick lab, cloned MqnA. Katherine A Hicks, Ealick lab, 
performed the structural studies on MqnA). 
_______
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Results and Discussion 
HPLC analysis of the MqnA reaction mixture: Genetic studies previously identified 
MqnA as essential for futalosine formation. To identify the reaction catalyzed by MqnA, 
the mqnA gene from T. thermophilus HB8 (TTHA0803) was amplified by PCR, cloned 
into the p28nT expression vector, overexpressed in E. coli BL21 (DE3), and purified by 
Ni-NTA affinity chromatography (Figure 4.2). Incubation of chorismate with MqnA 
resulted in the formation of a new product as shown in the HPLC chromatogram (Figure 
4.3), which was identified as 3-[(1-carboxyvinyl)- oxy]benzoic acid, 53 by NMR and 
MS analysis and comparison with an authentic synthetic reference compound.
147
 Shown
below is the SDS-PAGE analysis of MqnA in Figure 4.2 [The molecular weight is ~30.5 
kDa. A) Protein molecular weight markers and B) Purified MqnA)] 
Figure 4.2: SDS-PAGE analysis of MqnA. 
B A 
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Neither adenosine/inosine nor phosphoenolpyruvate/pyruvate was accepted as substrate 
by MqnA in these assays as previously proposed. Formation of aminofutlaosine (or 
futalosine) was not observed in the reaction mixture after analysis by HPLC and LCMS. 
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Figure 4.3: HPLC analysis of the reaction catalyzed by MqnA.
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[Blue trace: chromatogram of the full reaction mixture (MqnA + chorismate) Red trace: 
chromatogram of the control reaction mixture lacking MqnA. The inset shows the 
structure of the identified and characterized MqnA reaction product, 53] 
Characterization of compound 53 formed in the MqnA reaction: The compound 
formed from chorismate in the MqnA catalyzed reaction was purified by HPLC and 
characterized by NMR (Figures 4.4-4.7, Figure 8, Appendix A) and MS (Figure 4.8).  
Chorismate (3 mM) was incubated with MqnA (400 µM) in 100 mM Tris-HCl buffer 
(pH 7.5) and the reaction was allowed to proceed for 3 hrs. The protein was removed by 
ultrafiltration using 10 kDa centrifugal filters. The reaction product was purified by 
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HPLC (eluted at 5.1 min) and characterized by NMR (Figures 4.4-4.8) and LC-MS 
analysis (Figure 4.9).
147 
 
 
Figure 4.4: 
1
H NMR (500 MHz, CD3OD) spectrum of compound  53.
147 
 
 
 
 
Figure 4.5: 
13
C NMR (125 MHz, CD3OD) spectrum of compound 53.
147 
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Figure 4.6: 
13
C DEPT-135 spectrum (125 MHz, CD3OD) of compound 53.
147 
Figure 4.7: 
1
H-COSY spectrum of compound 53.
147
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Figure 4.8: HSQC spectrum of compound 53.
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Figure 4.9: ESI-MS (negative ion mode) analysis of compound 53.
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[In the mass spectrum, m/z 207.03, [M-H]
-
 corresponds to 3-((1-carboxyvinyl) oxy) 
benzoic acid, 53 (theoretical m/z 207.03)] 
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Synthesis of compound 53:The synthetic scheme for making 53 as a authentic reference 
compund to complete MqnA product characterization is shown Scheme 4.1.
148, 149 
Scheme 4.1: Synthetic scheme for 3-((1-carboxyvinyl) oxy) benzoic acid, 53 
Mechanistic studies on MqnA: Since the leaving groups in chorismate are not in an anti 
periplanar arrangement, the classical E2 elimination is not likely in this dehydration 
reaction. However, an E1 or E1cb mechanism is probable in this reaction. Following 
mechanistic proposal (Figure 4.10) is put forward for MqnA through the carbocation 58 
(E1 mechanism) or carbanion 59 (E1cb mechanism). 
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Figure 4.10: Mechanistic proposal for MqnA. 
To differentiate between these two mechanisms, MqnA reaction was run in deuterated 
buffer and incorporation of deuterium was looked for in unreacted starting material 
chorismate by NMR spectroscopy. Incorporation of deuterium into C-3 of chorismate 
would provide evidence for an E1cb mechanism. The reaction ([Chorismate] = 500 µM, 
[MqnA]= 1 µM) was performed in 100% deuterated buffer (potassium phosphate, pH 
7.5) and quenched after 5 min using 6M guanidine hydrochloride. The NMR spectra of 
the starting material chorismate and unreacted chorismate in the reaction mixture were 
compared to see if there is any difference in the peak shapes or splitting patterns of 
hydrogens at C-2 and C-3 due to H/D exchange (Figure 4.11 and 4.12). However, no 
such difference was observed in NMR spectra suggesting that H/D exchange is not 
occurring. This argued against the E1cb mechanism. 
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Figure 4.11: NMR spectrum of the MqnA reaction mixture 
Figure 4.12: Comparison of NMR spectra of unreacted chorismate and substrate. 
Blue trace: Unreacted chorismate after the reaction 
Red trace:  Chorismate substrate 
a 
b 
a b 
d 
e 
f 
f’ 
Product peaks 
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Steady state kinetics parameters for MqnA: Steady state kinetics parameters for MqnA 
were determined by varying chorismate concentrations while keeping fixed MqnA 
concentration and monitoring the formation of 3-[(1-carboxyvinyl) oxy]-benzoic acid, 
53 by HPLC using the method described above (The buffer used in HPLC analysis was 
100 mM potassium phosphate, pH 6.6).
147
 Each reaction mixture containing different
concentrations of chorismate (50 µM, 100 µM, 150 µM, 250 µM, 500 µM, 750 µM, 1 
mM and 1.5 mM) in 100 mM Tris-HCl buffer (pH 7.5) was divided into 90 µL and 10 
µL of 1 µM MqnA was added to achieve a final concentration of 0.1 µM. For each set of 
chorismate concentrations, the reaction was quenched at various time points by adding 
an equal volume of 8M guanidine hydrochloride. Protein was removed by ultrafiltration.  
Each sample was analyzed by HPLC and the amount of 3-[(1-carboxyvinyl) oxy]-
benzoic acid, 53 formed was plotted against time for each set of substrate concentrations. 
The initial linear slopes from each set of reactions were then plotted against the 
chorismate 39 concentrations and fit to the Michaelis Menten equation using 
KaleidaGraph (Synergy Software). The kcat and Km for MqnA were found out to be 1.27 
±.02 s
-1
 and 161.6 ± 7.1 µM respectively (Figure 4.13).
147 
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Figure 4.13: Michaelis-Menten plot for MqnA.
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Structural studies on MqnA: The structural studies are performed on a D. radiodurans 
R1 ortholog (DrMqnA) of T. thermophilus MqnA (TTHA0803) and 3-hydroxybenzoic 
acid (a structural analog of the product 53) was used in co-crystallization studies 
(Katherine A Hicks, Ealick lab, Cornell University, unpublished results). 
Overall structure of DrMqnA:  DrMqnA crystallized in the C222 space group, and 
contained two protomers in the asymmetric unit (Figure 4.14A).  Electron density was 
present for 271 residues, with the exception of disordered loop regions of residues at the 
N-terminus consisting of residues 1-16.  The protomer consists of 10 β-strands and 11 α-
helices (by Katherine Hicks, Ealick lab, Cornell University). 
V/E (s
-1
) 
[Chorismate] (µM) 
kcat   =1.27 ±.02 s
-1
Km   =161.6 ± 7.1 µM 
kcat/ Km  = 7.8 ×10
3 
s
−1 
M
−1
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DrMqnA active site: DrMqnA was co-crystallized with a product analog 3-
hydroxybenzoic acid (3-HB). This analog makes minimal interactions with DrMqnA.  
The only residue that makes significant interactions with 3-HB is Asn26 (Figure 4.14B), 
which hydrogen bonds with the carboxylate group on 3-HB orienting the substrate 
analog in the active site (by Katherine Hicks, Ealick lab, Cornell University). 
It was observed form the active site structure of MqnA (Figure 4.14 B) that no protein 
derived acid/base residues are present near the leaving groups of bound product analog 
suggesting that both elimination mechanisms could be wrong. Moreover, this also 
explains the results of the NMR experiment in which no H/D exchange was observed in 
unreacted chorismate. We conclude that the carboxylic acid group of the pyruvic acid 
side chain of chorismate 39 is participating in the dehydration mechanism. We propose 
that it first protonates the hydroxyl group at C-4, making it a good leaving group, water. 
This leads to the formation of intermediate 60 with carbocation character at C-4, which 
lowers the pKa of the hydrogen at C-3 and it is being abstracted by the hydrogen bonded 
water (Figure 4.15). 
67 
Figure 4.14: Crystal structure of MqnA.  
[A) Overall structure B) MqnA active site with 3-HB bound] 
A
B
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Figure 4.15: Proposed mechanism for MqnA 
 
Formation of compound 53 in the MqnA reaction raised questions whether it is an on-
pathway intermediate in the biosynthesis of menaquinone or whether it is just an off-
pathway shunt product. Further studies are required to confirm this observation. This 
also proves the original proposal for futalosine formation wrong and indicates that some 
additional enzymes or cofactors are necessary to complete this transformation. 
 
D. radiodurans R1 feeding study using [U-
13
C10]-chorismate: Dienococcus 
radiodurans synthesize menaquinone by the futalosine dependent pathway.
123
 Hence, in 
an in vivo experiment menaquinone biosynthetic precursor 39 ([U-
13
C10]-chorismate 
isolated from the E.coli KA12 mutant, a chorismate overproducing strain, Figure B1 and 
B2 Appendix B)
150
 was fed to D. radiodurans R1 in order to look for 
13
C label 
incorporation in menaquinone, 26. About 400 ml of D. radiodurans R1 culture was 
grown with ~85 mg of labeled chorismate. Menaquinone was extracted from the dried 
cell pellets of D.radiodurans using 2:1 chloroform: methanol solvent mixture and 
analyzed by LC-MS to look for the incorporation of the 
13
C label from chorismate into 
menaquinone (Figure 4.16). 
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Figure 4.16: D. radiodurans R1 Feeding study using [U-
13
C10]-chorismate
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Figure 4.17: LC-MS chromatogram of the isolated menaquinone
*
*
[ESI-MS (positive ion mode) analysis of MK-8 26. In the mass spectrum, m/z 717.56,
[M+H]
+ 
corresponds to, 26 (theoretical m/z 717.56). A [M+8] MK-8 peak is found with
m/z 725.58]. 
In the LC-MS analysis (Figure 4.17) we have found an M+8 peak with m/z 725.58 along 
with the parent menaquinone peak (~10% of the parent M peak at m/z 717.56). This 
experimental result indicated that at least eight carbons from chorismate may have 
M+8 peak 
70 
incorporated into menaquinone (Figure 4.18). This suggests that chorismate may be 
incorporated into menaquinone as one single unit, probably with the loss of two carboxyl 
groups during this process. Involvement of inosine or phosphoenolpyruvate is probably 
not required as previously proposed.
123 
Figure 4.18: Probable incorporation of carbons from labeled 39 into MK-8, 26. 
Conclusion 
While non-enzymatic acid catalyzed dehydration of chorismate is well known,
151
surprisingly, enzymatic catalysis of this reaction has not been previously reported. 
MqnA is, to the best our knowledge, the first example of an enzyme that catalyzes the 
dehydration of chorismate to form the aromatic compound 3-[(1-carboxyvinyl) oxy]-
benzoic acid, 53.
147
 Although, earlier we predicted that this elimination reaction is
occurring either through E1 or E1cb mechanism, but absence of acid base residue pair in 
the substrate binding pocket led us reject this proposal. However, we believe that 
dehydration of chorismate to the aromatic product probably occurs with the assistance of 
the neighboring carboxylate group of the pyruvic moiety of chorismate and enzyme 
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active site perhaps provides the perfect orientation and proximity of the groups required 
for this dehydration. We put forward a mechanistic proposal based on this hypothesis. 
Moreover, it was also found that adenosine/inosine and phosphoenolpyruvate/pyruvate 
are not substrates for MqnA as previously proposed.
123
 Formation of futalosine was not
observed when chorimate, inosine and phosphoenolpyruvate were incubated with MqnA. 
Hence, it is quite possible that additional cofactors and/or enzymes are required for this 
transformation. At this point, it is difficult to say whether the aromatic product, 53 is an 
on pathway intermediate or an off pathway shunt product in the menaquinone 
biosynthesis pathway. However, the in-vivo feeding study suggests that chorismate, 39 is 
probably directly involved in forming the naphthoquinone core structure of 
menaquinone 26, which might indicate that 53 is actually an on pathway intermediate. 
Further studies are required to confirm our results and the mechanistic hypothesis. 
Experimental procedures 
General methods and materials: Molecular biology manipulations were carried out 
using standard techniques.
64, 152
 PCR amplifications were performed using an automatic
thermocycler (Mastercycler, Eppendorf) and oligonucleotide primers were synthesized 
by Integrated DNA Technologies. Phusion DNA polymerase was obtained from New 
England BioLabs. The cloning vectors p28nT and pTHT are derivatives of pET-28, 
which was purchased from Novagen. Plasmid mini-prep and PCR purification kits were 
acquired from Qiagen or Fermentas. DNA fragments were purified from agarose gels 
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with the Zymoclean Gel DNA Recovery Kit from Zymo Research. All restriction 
enzymes and T4 DNA ligase were purchased from New England Biolabs. DNA 
sequencing was performed using the Applied Biosystems Automated 3730 DNA 
Analyzer at the Cornell University Life Sciences Core Laboratories Center (Cornell 
BioResource Center). Escherichia coli strains DH5α or MachI (Invitrogen) were used as 
recipients for transformations during plasmid construction as well as for plasmid 
propagation and storage. Growth media were obtained from Difco. Reagents were 
purchased from Sigma-Aldrich unless stated otherwise. 
Expression constructs for His6-MqnA: Chromosomal DNA from Deinococcus 
radiodurans R1 (13939D-5), and Thermus thermophilus HB8 (27634D-5) was 
purchased from American Type Culture Collection (ATCC) and used as the template for 
PCR amplification of mqnA. The genes were amplified by PCR using the primer 
sequences listed below. The product containing the desired gene was excised from an 
agarose gel, purified and digested with the appropriate restriction enzymes, repurified, 
and then ligated into similarly digested and purified p28nT or pTHT. The final 
constructs encode the gene product with six histidine residues and a TEV protease 
recognition sequence (underlined font) appended to the N-terminus: p28nT, 
MGSSHHHHHHSSGENLYFQGH; pTHT, MGSDKIHHHHHHSSGENLYFQGH. 
Competent E. coli DH5α cells were transformed with the sample. Cells were plated on 
LB
 agar (1.5%) supplemented with 50 μg/mL kanamycin (LabScientific) to select for 
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positive clones. Subsequently, clones were screened by colony PCR and the desired gene 
products were confirmed by DNA sequencing. 
p28nT-ttmqnA. The forward and reverse primers for ttmqnA gene amplification by PCR 
were designed with NdeI and BamHI restriction sites (indicated in underlined font), 
respectively, as TtMqnA FP: 5′- gggtagcatATGAGGCCCTACGTCCTGGGCCTTCCC-
3′ and TtMqnA RP: 5′-cccTAGGATCCTACTCAGGATAGAACATAGGGGCG-3′. 
pTHT-DrmqnA. The forward and reverse primers for drmqnA gene amplification by 
PCR were designed with NdeI and XhoI restriction sites (indicated in underlined font), 
respectively, as 
DrMqnA FP: 5′ gggtagcatatgACCAACCATCACCCATCATCTACTGGC-3′ and 
DrMqnA RP: 5′-ccctactcgagttaTGCTTCCTCACGCGCGCTCCGAAGG-3′. 
Expression and purification of His6-MqnA: Electrocompetent Escherichia coli BL21 
(DE3) (Novagen) cells were prepared using standard methods. The cells were freshly 
transformed with the pTHT or p28nT constructs containing the appropriate N-terminal 
hexa-histidine mqnA fusion. Single colony transformants were grown aerobically for 12-
15 h at 37 °C in 20 mL of LB
 medium supplemented with 40 μg/mL kanamycin (LB-
kan). Cells from the starter culture were added to 2 L of LB-kan, and the culture was 
grown aerobically at 37 °C until the A600 was 0.6-0.8. Expression was induced by the 
addition of 1 mM IPTG and the culture was grown aerobically at 15 °C for an additional 
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~ 16 h. Cells were harvested by centrifugation at 6,300×g in a Beckman Coulter Avanti 
J-26 XPI with a JLA-8.1000 rotor for 15 min at 4 °C. The medium was discarded and the 
cell paste (~ 2 g per liter of cell culture) was stored at –80 °C until use. Cells were 
thawed, resuspended in 20 mL of Lysis Buffer (50 mM potassium phosphate, pH 7.8 at 4 
°C, 150 mM NaCl), and then lysed by sonication on ice for 6 × 20 s using a Misonix 
Sonicator 3000 (24 W, 1.5 s pulse, 1.5 s pause). Cell debris was removed by 
centrifugation at 31,000×g in a Beckman Coulter Avanti J-E with a JA-17 rotor for 45 
min at 4 °C and the supernatant was clarified through a 0.45 μm syringe filter. The 
enzyme was purified by nickel affinity chromatography at 4 °C using a stepwise gradient 
of increasing imidazole concentration with a 5 mL HiTrap chelating HP column (GE 
Healthcare Life Sciences). Wash Buffers were prepared by combining the Lysis Buffer 
and Elution Buffer (50 mM potassium phosphate, pH 7.8 at 4 °C, 150 mM NaCl, 500 
mM imidazole) to give the final imidazole concentrations desired. The resin was charged 
with 2 CV of 0.1 M NiSO4, washed with 5 CV of filtered water to remove excess nickel, 
and equilibrated with 2 CV of Lysis Buffer. After loading the filtered protein sample, the 
resin was washed with 2 CV each of Wash Buffers containing 20 mM, 50 mM, 200 mM, 
and 500 mM imidazole. Fractions of 10 mL were collected and analyzed for purity by 
12% SDS-PAGE. His6-MqnA eluted from the column in the 200 mM imidazole Wash 
Buffer fractions. Nickel affinity column fractions containing the desired protein were 
pooled and concentrated from ~ 20 mL to ~ 3 mL using a centrifugal filtering device 
with a 10 kDa MWCO membrane (Millipore) and the buffer was exchanged to Final 
Buffer (50 mM potassium phosphate, pH 7.5 at 4 °C, 150 mM KCl, 30% glycerol) via 
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Econo-Pac 10DG size exclusion chromatography. SDS-PAGE analysis showed the 
molecular weight of MqnA as ~ 30.5 kDa (Figure S1). Protein concentrations were 
determined using the Bradford assay and A280 measurements. Typical yields were ~ 10 
mg per liter of cell culture. Proteins were stored at –80 °C. 
Characterization of 3- ((1-carboxyvinyl) oxy) benzoic acid, 53: Chorismate (3 mM) was 
incubated with MqnA (400 µM) in 100 mM Tris-HCl buffer (pH 7.5) and the reaction 
was allowed to proceed for 3 hrs. The protein was removed by ultrafiltration using 10 
kDa centrifugal filters. The reaction product was purified by HPLC (eluted at 5.1 min) 
and characterized by NMR and LC-MS analysis. 
HPLC method:  HPLC analysis using a linear gradient, at a flow rate of 1 mL/min was 
used with absorbance detection at 254 nm.  Solvent A is water, solvent B is 100 mM 
K2HPO4, pH 6.6 and solvent C is methanol: 0 min, 100% B; 5 min, 100 % B; 12 min, 48 
% A, 40 % B, 12 % C; 14 min, 50 % A, 30 % B, 20 % C; 18 min, 30 % A, 10% B, 60% 
C; 20 min, 100 % B; 25 min 100 % B.  The column used was a Supelcosil LC-18- T 
HPLC column (15 cm x 4.6 mm, 3 µM particle size). 
The purified compound was concentrated using a speedvac concentrator (Thermo 
Scientific) and dissolved in CD3OD for NMR analysis. The spectroscopic data are as 
follows (Figures 4.4, 4.5): 
1
H NMR (500 MHz, CD3OD):  7.78 (dt, J = 7.8, 1.35 Hz,
1H), 7.60-7.625 (m, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.25 (dddd, J = 8, 2.4, 1.1 Hz, 1H), 
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5.83 (d, J = 2.01 Hz, 1H), 5.09 (d, J = 2.01 Hz, 1H), 
13
C NMR (125 MHz, CD3OD): 
168.9, 165.3, 157.6, 151.5, 133.8, 131.0, 126.1, 124.0, 120.1, 107.3. DEPT-135 
13
C 
NMR (Figure 8, Appendix A): 133.8 (CH), 131.0 (CH), 126.1 (CH), 124.0 (CH), 120.1 
(CH), 107.3 (CH2). The 2D NMR spectra (COSY and HSQC) of 53 are shown in 
Figures 4.6 and 4.7 respectively.  LC-MS analysis of the compound, 53 (ESI, negative 
ion mode) yielded m/z of 207.03, [M-H]
 -
 (calculated m/z 207.03 m/z, Figure 4.8). 
 
LC-MS method: Samples were analyzed by reverse-phase HPLC on an Agilent 1200 
HPLC system equipped with a diode array UV-Vis detector and a thermostatted 
autosampler (10 °C). The stationary phase was Supelcosil LC-18-T (15 cm × 3 mm, 3 
µm particles), maintained at 22 °C. The LC eluent consisted of a gradient of 75% 
methanol in 25% water with 5 mM ammonium acetate buffer, pH 6.6 (0.4 mL/min flow 
rate). The percentages of ammonium acetate buffer (B) and methanol (M) at time t varied 
according to the following scheme: {t,M,B}: {0,0,100}, {2,0,100}, {10,35,65}, 
{15,57.5,42.5}, {18,100,0}, {23,100,0}; {26,0,100}; {33,0,100}. Compounds were 
detected using absorbance at 254 nm. UV-Vis spectra (190 – 640 nm) were also 
collected and evaluated. Mass data were collected using an in-line Bruker Daltonics 
micrOTOF-Q II ESI-Qq-TOF mass spectrometer (HyStar) in positive ion mode. 
 
Crystallization, data collection and processing:  Initial crystallization conditions were 
identified using the hanging drop vapor diffusion method (Crystal Screens 1 and 2, 
Hampton Research; Wizard Screens 1, 2, 3 and 4, Emerald Biosystems) at 18 °C.  
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Hanging drops were formed by mixing 1.5 L of reservoir solution with 1.5 L of 
protein sample.  Optimized crystals required a microseeding step using cat whiskers and 
a reservoir solution contained 0.1 M acetate (pH 5.5), 13% PEG 1500, 2.5 M sodium 
chloride (NaCl), and 1.5% 2-methyl-2,4-pentanediol (MPD).  Large rectangular shaped 
crystals grew to 500-600 m  50-100 m in two to four days.  To obtain the liganded 
structure, the crystals were removed from the hanging drop and placed in a sitting drop 
tray.  A sequential addition of 3-hydroxybenzoic acid (3-HB) was added to the crystals 
from 2-100 mM in 10 mM increments.  At each concentration, the crystals were 
transferred to a new drop and allowed to incubate for ~10 minutes.  The crystallization 
buffer supplemented with 100 mM 3-HB and 26% ethylene glycol was used as the 
cryoprotectant.  Samples were flash frozen by plunging into liquid nitrogen. Data sets 
were collected at the Cornell High Energy Synchrotron Source (CHESS) at beamline 
A1.  The data was collected on a single crystal over 180 using a 1 oscillation range at a 
wavelength of 0.9180 Å.  The crystals diffracted to 2.33Å resolution.  The space group 
was C222 with average unit cell parameters of a = 143 Å, b = 152 Å , and c = 75 Å.  The 
asymmetric unit consisted of two chains corresponding to a Matthews’s coefficient of 
2.26 Å
3
/Da solvent content of 46 %.
153
  Data were indexed, integrated, and scaled using
HKL-200
66
 (by Katherine Hicks, Ealick lab, Cornell University).
Structure determination, model building and refinement: The structure was determined 
by molecular replacement using MOLREP
67
 with protein DR0370 from Deinococcus
radiodurans, Pfam DUF178 as the search model
154
 (PDB entry 2I6E).  Initial refinement
78 
was carried out using Refmac 5.0 and the CCP4i interface
153, 155
.  Iterative rounds of
manual model building were performed with COOT
156
 and later rounds of refinement
were carried out using PHENIX
156, 157
 (by Katherine Hicks, Cornell University)
Isolation and purification of chorismate: Chorismate was purified as reported before.
150 
The growth media contained following components (per 1L) : Yeast extract (2g), casein 
hydrolysate (2g), anhydrous MgSO4 (0.1g),citric acid (1.83g),K2HPO4 (10g), 
Na(H)(NH4)PO4.4H2O (3.5g), Tryptophan (41mg), glucose (1.6 g), tetracycline (12 
µg/mL). The accumulation media contained following components (per 1L): Glucose 
(18g), Na2HPO4 (12.8g), KH2PO4 (1.36g), NH4Cl (2.74 g), MgCl2.6H2O (20.3 mg), 
tryptophan (3mg). [U-
13
C6]- Glucose in both growth media and accumulation media.
Growth procedure: 1L sterile growth medium was inoculated with 5 mL of O/N culture 
of E.coli KA-12 strain and grown at 30°C with vigorous shaking (250-300 rpm) for 
~20hrs. Then it was centrifuged to remove the growth media. The cells were re-
suspended in 1L accumulation media and incubated with shaking (~250 rpm) at 30°C for 
16-20 hrs. The accumulation of chorismate was checked by taking the O.D. of a 100 µL 
aliquot of the accumulation media. The aliquot was centrifuged and the supernatant was 
diluted to 1:20 in water and checked OD (275 nm) (should be ~0.3-0.7). When the O.D. 
reached about this value, the accumulation media was centrifuged and apply it for 
further purification. 
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Purification procedure: Dowex-Cl 1x8 beads (50-100 mesh, 40g) were washed with 
1M HCl (~150mL), followed by thorough rinsing with water until the pH is neutral. This 
is followed by washing the beads with 1M NaOH (~150 mL), followed by rinsing with 
water until the pH is <8. Then, the accumulation media was made basic with 10M NaOH 
(to pH 8.5) and applied it to the column packed with the beads (pre-running with water). 
The column was washed column with water and chorismate is eluted with 2M NH4Cl 
(pH 8.5) at slower flow rate (~2.5 ml/min). 15 ml fractions (Chorismic acid elutes early 
with a visible dark brown color) were collected and fractions with OD 275 >0.25 (in a 
1:100 dilution) were pooled for further purification. The collected fractions (130ml) 
were acidified to pH 1.5 with HCl and extracted 5X with 100 ml of cold diethyl ether. 
The ether extracts were dried with anhydrous MgSO4, filtered and concentrated to <10 
ml using Rota vapor. The ether concentrate was cooled to 0°C and petroleum ether was 
slowly added drop wise and swirled the flask until a light yellow precipitate forms and 
remains in the solvent (At this point adding chorismic acid helps in faster 
crystallization). Allowed the chorismic acid to crystallize (~3 hrs) and then added more 
petroleum ether to ensure complete crystallization (left at -20°C overnight). The solvent 
was poured off onto vacuum filter without pouring out crystals. The crystals were dried 
by lyophilization for ~6 hrs and stored as powder form at -80°C (~330mg of chorismate 
from 1L culture was obtained). 
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CHAPTER V 
MENAQUINONE BIOSYNTHESIS: RECONSTITUTION AND 
CHARACTERIZATION OF A UNIQUE RADICAL SAM ENZYME, 
AMINOFUTALOSINE SYNTHASE (MqnE)
*# 
Introduction 
It was proposed in the futalosine dependent menaquinone biosynthesis pathway that 
MqnA catalyzes the formation of futalosine from chorismate, inosine and 
phosphoenolpyruvate (Figure 3.8).
123
 Since we were unable to reconstitute the formation
of futalosine or aminofutalosine using MqnA alone,
147
 we considered the possible
involvement of additional enzymes and/or cofactors for this transformation. Three 
possible pathways for the formation of aminofutalosine were considered (Figure 5.1). 
Paths A and B require a thiamin pyrophosphate dependent ketoacid decarboxylase, while 
path C requires a radical SAM enzyme. To determine which path was used, we analyzed 
the gene neighborhood of the identified menaquinone biosynthetic genes and our 
analysis yielded one promising gene (now named as mqnE), encoding a putative radical 
SAM enzyme that frequently clustered with menaquinone biosynthetic genes (SCO4494 
in S. coelicolor). The studies described herein are aimed at characterizing this putative 
radical SAM enzyme and its relevance in the menaquinone biosynthesis pathway. 
*Part of this chapter is reprinted with permission from “Menaquinone Biosynthesis: Formation
of Aminofutalosine Requires a Unique Radical SAM Enzyme” by Mahanta, N.; Fedoseyenko, 
D.; Dairi, T.; Begley, T. P., 2013. J. Am. Chem. Soc., 135, 15318-15321, Copyright [2013] by 
American Chemical Society. 
#
(Nilkamal Mahanta performed the biochemical studies. Dmytro Fedoseyenko synthesized 
compounds 53 and 50). 
______
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Figure 5.1: Three possible pathways for the formation of aminofutalosine, 64.
147 
Results and Discussion 
Bioinformatics analysis: The gene neighbourhood of the identified menaquinone 
biosynthetic genes was analyzed for additional genes encoding a putative thiamin 
pyrophosphate dependent decarboxylase or a putative radical SAM enzyme using the 
SEED database (http://theseed.uchicago.edu/FIG/). Figure 5.2 summarizes some relevant 
portion of the gene cluster in the neighborhood of MqnA (MqnA is shown in black, 
MqnB in purple, MqnC in green and MqnD in Cyan) and other menaquinone 
biosynthetic genes in some of the organisms synthesizing menaquinone by the futalosine 
dependent pathway.
123
82 
Figure 5.2: Biosynthetic gene cluster of some menaquinone producing organisms. 
83 
This bioinformatics analysis (Figure 5.2) shows the presence of a gene named SCO4494 
(shown in red, nomenclature is based on S.coelicolor genome) clustered along with 
MqnA in some organisms (such as T. thermophilus) and along with the other genes of 
menaquinone biosynthesis in some other organisms (such as S. avermitilis). NCBI blastp 
analysis using the amino acid sequence corresponding to SCO4494 indicated homology 
with some known radical SAM enzymes (such as biotin synthase, lipoate synthase) and 
contains a characteristic CX3CX2C motif required to bind the [4Fe-4S] cluster.
147
 An
amino acid sequence from a T. thermophilus orthologue, TTHA0804 shows this binding 
motif (Figure B, Appendix B). With this finding, we wanted to experimentally validate 
whether a putative radical SAM enzyme encoded by the gene SCO4494 could be a 
possible candidate involved in the formation of aminofutalosine (or futlaosine). 
Enzyme characterization (TTHA0804 from T. thermophilus HB8): To test the 
hypothesis that aminofutalosine, 64 is formed via path C (Figure 5.1) using the newly 
discovered gene SCO4494, we decided to use the recombinant enzyme. An orthologue 
from T. thermophilus HB8 (Figure B3, Appendix B), TTHA0804 was PCR amplified, 
cloned into the pQE-30 expression vector, and overexpressed in E. coli M15 (pREP4). 
The resulting His6-tagged MqnE protein was purified by Ni-NTA affinity 
chromatography under anaerobic conditions (Figure 5.3 shows the SDS-PAGE analysis 
in which A is the molecular weight marker and B is the purified MqnE. The molecular 
weight is ~42.6 Da). The purified protein had an absorbance maximum at 415 nm, which 
disappeared upon treatment with excess dithionite or on exposure to oxygen, consistent 
84 
with the presence of the predicted [4Fe-4S] cluster (Figure 5.4). Iron and sulfide analysis 
yielded 2.4 irons and 2.8 sulfides per monomer of the enzyme, indicating incomplete 
reconstitution of the cluster. The cluster incorporation was improved by co-expression of 
an E.coli Fe-S cluster biosynthetic protein suf 
158 
along with TTHA0804. Iron and sulfide
analysis of the purified protein yielded 3.7 irons and 4.2 sulfides per monomer of 
protein. We termed it as MqnE. 
Figure 5.3: SDS-PAGE analysis of MqnE (TTHA0804). 
A B 
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Figure 5.4: UV−visible spectra of MqnE (TTHA0804).147
[Blue trace: protein “as isolated” enzyme, Red trace: dithionite (excess) treatment of the 
“as-isolated” sample, Green trace: aerobic oxidation of the “as-isolated” 
sample.Absorbance at 415 nm was observed due to the presence of the bound Fe-S 
cluster] 
MqnE (as isolated) was analyzed by EPR spectroscopy and it was found that the EPR 
spectral properties of the bound Fe-S cluster is consistent with a [3Fe-4S]
+
 cluster with g
value of 2.01 (Figure 5.5).
159
 On in-vitro reconstitution using iron and sulfide and after
reduction with sodium dithionite, it is converted to a catalytically active [4Fe-4S]
+
cluster. Such an observation has been made some other radical SAM enzymes (such as 
PqqE involved in Pyrroloquinoline quinone biogenesis)
160
and other Fe-S cluster 
containing enzymes (such as Aconitase).
161 
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Figure 5.5: EPR spectrum of the Fe-S cluster  bound to MqnE ( as-isolated form). 
 
HPLC analysis of the MqnE reaction mixture: To investigate the involvement of MqnE 
(TTHA0804) in the formation of aminofutalosine, 3-[(1-carboxyvinyl) oxy]- benzoic 
acid, 53 was prepared by incubating chorismate with MqnA (Figure 4.3) or by chemical 
synthesis (Scheme 4.1). Compound 53 (2 mM) was then incubated anaerobically with 
MqnE (200 μM) in the presence of S-adenosylmethionine (2 mM) and excess sodium 
dithionite. After 10 h, the reaction was quenched with 8 M guanidine-HCl, protein was 
removed by ultrafiltration, and the reaction mixture was analyzed by reverse-phase 
HPLC. This analysis showed the formation of a new compound in the HPLC 
chromatogram which elutes at 20.2 min (Figure 5.6). It was purified from reaction 
mixture using HPLC and characterized by 1D and 2D NMR (Figures 5.7-5.11) and MS 
analysis (Figure 5.12). This analysis suggested that the new compound forming in the 
MqnE reaction is 6-aminodeoxyfutalosine (or aminofutalosine), 64.
147 
g = 2.01 
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Figure 5.6: HPLC analysis of the MqnE reaction mixture.
147 
[Blue trace: chromatogram of the full reaction mixture (MqnE + 53 + SAM + dithionite); 
Red trace: chromatogram of the control reaction mixture lacking MqnE; Green trace: 
chromatogram of the control reaction mixture lacking substrate 53, showing low levels 
of the uncoupled production of 5′-deoxyadenosine. No signals at 20.2 and 19.5 min were 
obtained in the control reactions individually lacking SAM or dithionite (data not 
shown). The inset shows the structure of the identified MqnE reaction product, 64, 
which was also, characterized by 1D and 2D NMR and MS spectrometry]  
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NMR and MS characterization of aminofutalosine, 64: 
 
 
Figure 5.7: 
1
H NMR spectrum (500 MHz, D2O) of aminfutalosine, 64.
147 
 
 
Figure 5.8: 
13
C NMR (125 MHz, D2O) of aminofutalosine, 64.
147 
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Figure 5.9: 
13
C DEPT-135 NMR (125 MHz, D2O) spectrum of aminofutalosine, 64.
147 
 
 
 
Figure 5.10: 
1
H COSY spectrum of aminofutalosine,64.
147 
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Figure 5.11: HSQC spectrum of aminofutalosine, 64.
147 
136.06
414.14
+MS, 13.4-13.5min #(800-806), Background Subtracted
0.00
0.25
0.50
0.75
1.00
1.25
5x10
Intens.
100 150 200 250 300 350 400 450 m/z
Figure 5.12:  LC-MS (ESI, positive ion mode) analysis of aminofutalosine, 64.
147 
*
[In the mass spectrum, m/z 414.14, [M+H]
+
 corresponds to aminofutalosine 64
(theoretical m/z 414.14) and m/z 136.06 corresponds to adenine derived from 
aminofutalosine (theoretical m/z 136.06)] 
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Deamination of aminofutalosine 64 as a confirmation of its structure: The 6-
aminodeoxyfutalosine deaminase
162, 163
 SCO5662 (100 µM) was incubated with 
biosynthesized aminofutalosine 64 in the presence of Mn
2+
 (250 µM) for 3 hrs in 100 
mM Tris-HCl buffer (pH 7.5). The reaction mixture (100 µL) was then treated with an 
equal volume of 8M guanidine-HCl and the protein was removed by ultrafiltration using 
10 kDa centrifugal filters (Pall Life Sciences). The reaction mixture was analyzed by 
reverse phase HPLC. The reaction product (eluted at 19.6 min) was confirmed as 
futalosine 49, by co-migration with an authentic sample isolated from an S. coelicolor 
mutant
 123 
(obtained from Tohru Dairi lab, Figure 5.13).
147 
LC-MS (ESI, positive ion 
mode) analysis of the product showed m/z = 415.13 [M+H]
+
 which corresponds to 49 
(theoretical m/z = 415.13, Figure 5.14).
147
  
 
 
Figure 5.13: HPLC analysis of the aminofutalosine deaminase reaction mixture.
147
  
[Blue trace: chromatogram of the full reaction mixture (TTHA0804 reaction products + 
SCO5662 + Mn
2+
); red trace: chromatogram of the standard futalosine.
147
The substrate, 
aminofutalosine 64, elutes at 20.2 min on the chromatogram]. 
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Figure 5.14: LC-MS analysis of the aminofutalosine deaminase reaction.
147
 [In the mass 
spectrum, (m/z 415.13, [M+H]
+ 
corresponds to futalosine 49, theoretical m/z = 415.13 
and m/z 137.05 corresponds to hypoxanthine derived from futalosine 28, theoretical m/z 
137.05)] 
 
Conversion of aminofutalosine, 64 to 50 as a confirmation of its structure: The 
hydrolase HP0089
162
 (100 µM) was incubated with biosynthesized aminofutalosine, 64 
for 3 hrs. The reaction mixture (150 µL) was treated with an equal volume of 8M 
guanidine-HCl, protein was removed by ultrafiltration and analyzed by reverse phase 
HPLC. The reaction product was confirmed as compound 50, by co-migration with an 
authentic synthesized sample of 50 
144
 (eluted at 16.8 min, Figure 5.15) and by LC-MS 
analysis (Figure 5.16).
147 
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Figure 5.15: HPLC analysis of the aminofutalosine nucleosidase reaction mixture.
147
 
[Blue trace: chromatogram of the reaction mixture; red trace: chromatogram of the 
standard 50.
144
The substrate, aminofutalosine, 64 elutes at 20.2 min on the 
chromatogram] 
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Figure 5.16: LC-MS analysis of the aminofutalosine nucleosidase reaction.
147
 [In the 
mass spectrum, m/z 297.10 corresponds to 50, theoretical m/z 297.10, [M+H]
+
 and m/z 
279.09 corresponds dehydrated 50 ( [M-H2O+H]
+
)] 
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Catalytic capacity of MqnE: The MqnE reaction mixtures were also analyzed to 
determine if MqnE was catalytic. 3-[(1-carboxyvinyl) oxy]-benzoic acid, 53 (2 mM) was 
incubated with SAM (2.5 mM) and MqnE (120 µM) in the presence of excess sodium 
dithionite for 12 hrs. The reaction was quenched with 8M guanidine hydrochloride and 
MqnE was removed by ultrafiltration. The amount of aminofutalosine formed was 
quantified by HPLC analysis (64 eluted at 20.2 min, Figure 5.6) to yield the product 
concentration of 1.7mM demonstrating that the reaction is catalytic (based on a standard 
curve, Figure B4, Appendix B). In other words, with the current enzyme preparations, 1 
equivalent of enzyme gives 14 equivalents of aminofutalosine 64. 
Fate of the carbon lost during the MqnE reaction: The MqnE reaction mixtures were 
also analyzed to determine the fate of the carboxylate of compound 53. NMR analysis of 
the MqnE reaction mixture, run using [
13
C]-53, demonstrated the formation of
bicarbonate and not formate, suggesting that the carboxyl group of 53 is lost in a 
decarboxylation reaction (Figure 5.17).
147
95 
Figure 5.17: 
13
C NMR (125 MHz, D2O) analysis of the MqnE catalyzed reaction.
147
[(A) Blue trace: spectrum of the full reaction mixture (MqnE + 
13
C labeled 53 + SAM,
66 + dithionite); (B) red trace: spectrum of the control reaction mixture lacking 
substrate, 53; (C) green trace: spectrum of the control reaction mixture lacking MqnE ; 
(D) violet trace: spectrum of the control reaction mixture lacking SAM;  (E) yellow 
trace: spectrum of the control reaction mixture lacking dithionite ; (F) brown trace: 
spectrum of standard 
13
C sodium bicarbonate. The signal observed in spectrum A at
160.01 ppm matched with the chemical shift of the bicarbonate signal of spectrum F]. 
A) MqnE full reaction
B) No substrate control
C) No MqnE control
D) No SAM control
E) No dithionite control
F) 
13
C bicarbonate standard 
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Mechanistic proposal for the radical SAM enzyme MqnE:  Radical SAM enzymes are 
among the most interesting family of enzymes that catalyze several mechanistically 
intriguing reactions found in biological systems.
164-168
 In these enzymes,
5'’deoxyadenosyl radical abstracts a hydrogen atom directly from the substrate or via a 
protein based radical and generates 5’-deoxyadenosine.164-168 The resulting substrate
radical then further undergoes remarkable rearrangement and/or fragmentation reactions 
to yield the product. Radical SAM enzymes are particularly prevalent in biosynthetic 
pathways of cofactors and catalyze various complex rearrangement reactions (such as 
ThiC in thiamin biosynthesis, MoaA in molybdopterin biosynthesis and CofG/CofH or 
FbiC in coenzyme F420 bisynthesis).
169
However, the radical SAM enzyme MqnE discovered in this pathway represents a 
unique example of this superfamily. On the basis of our experimental results so far, a 
mechanistic proposal for the aminofutalosine synthase (MqnE)-catalyzed reaction is 
outlined (Figure 5.18).
147
 First, reductive cleavage of S-adenosylmethionine (SAM) 66
with the help of the reduced [4Fe-4S] cluster generates 5’-deoxyadenosyl radical 67 and 
methionine 68. Addition of the radical 67 to the vinyl double bond of compound 53 
gives the captodative radical 69. A non-enzymatic side reaction showing a similar 
radical addition has been reported in a pyruvate formate lyase-derived peptide in which 
the active-site glycine was replaced with dehydroalanine.
170
 Rearrangement of this
radical via 70 gives 71. Such rearrangements have previously been proposed but not 
mechanistically well characterized.
171-173
 Decarboxylation of 71, facilitated by the
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alkoxy radical, gives 72. A final electron transfer from 72 to the [4Fe-4S]
2+
 cluster 
completes the formation of 64.
147 
 
Figure 5.18: Mechanistic proposal for the radical SAM enzyme MqnE.
147
  
 
Conclusion 
Previously, it was proposed in this biosynthetic pathway, MqnA (SCO4506) catalyzes 
the coupling of chorismate, 39,  adenosine/inosine 48 , and phosphoenolpyruvate, 38 to 
form aminofutalosine, 64 or futalosine, 49 using unknown chemistry.
123
 However, 
failure to reconstitute the formation of futalosine in the MqnA reaction by this proposed 
route suggested that additional enzymes and cofactors could be involved in this 
transformation. Our discovery of the radical SAM enzyme MqnE, guided by 
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bioinformatics analysis followed by in-vitro reconstitution indicated that this was the 
missing enzyme on the pathway.
147
 Aminofutalosine is further converted to futalosine by 
6-aminodeoxyfutalosine deaminase.
147, 162, 163
 Hence, what was previously believed to be 
a one enzyme (MqnA) catalyzed transformation
123
 is actually a three enzymes (MqnA, 
MqnE and deaminase) mediated reaction (Figure 5.19).
147
 This finding also provided the 
evidence that chorismate derived compound 53 in the MqnA reaction is actually an on-
pathway intermediate and also supports our in-vivo feeding studies. 
 
 
Figure 5.19: Revised route for futalosine formation in menaquinone biosynthesis. 
 
In summary, we have reconstituted the formation of aminofutalosine, 64 in the new 
menaquinone biosynthesis pathway. This reaction involves the addition of an adenosyl 
radical to the enol ether double bond of chorismate-derived 53 (Figure 5.20) and 
represents a new catalytic motif in radical SAM enzymology, where all previously 
99 
characterized enzymes
164-168
 except for diphthamide synthase
174
 use the adenosyl radical
to abstract a hydrogen atom from the cosubstrate or from an active-site glycine. 
Figure 5.20: New reaction motif represented by the radical SAM enzyme MqnE 
In other words, the MqnE-catalyzed reaction represents an efficient way to add adenosyl 
or ribose units to a double bond to generate an intermediate (such as 74 in Figure 5.21A) 
with rich biosynthetic potential. Other examples of this efficient catalytic motif are likely 
to emerge in natural product biosynthetic pathways (Figure 5.21A). Griseolic acid, 77  
biosynthesis presents one possible example in which intermediate 76 may be formed by 
addition of the 5’-deoxyadenosyl radical, 67 to fumaric acid, 75 (Figure 5.21B).175, 176 
100 
Figure 5.21: Potential applications and examples of MqnE type chemistry.
147
[(A) Adenosyl radical addition to a double bond generates a new, potentially versatile 
biosynthon 74 enabling chemistry at both C1 and C5 of ribose. (B) Griseolic acid 
biosynthesis presents a possible example of this chemistry.]
175, 176 
Experimental Procedures
147
General methods and materials: Molecular biology manipulations were carried out 
using standard techniques.
64, 152
 PCR amplifications were performed using an automatic
thermocycler (Mastercycler, Eppendorf) and oligonucleotide primers were synthesized 
by Integrated DNA Technologies. Phusion DNA polymerase was obtained from New 
England BioLabs. Plasmid mini-prep and PCR purification kits and E. coli M15 
(pREP4) cells were acquired from Qiagen or Fermentas. DNA fragments were purified 
from agarose gels with the Zymoclean Gel DNA Recovery Kit from Zymo Research. All 
restriction enzymes and T4 DNA ligase were purchased from New England Biolabs. 
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Escherichia coli strains DH5α or MachI (Invitrogen) were used as recipients for 
transformations during plasmid construction as well as for plasmid propagation and 
storage. Growth media were obtained from Difco. Reagents were purchased from 
Sigma-Aldrich unless stated otherwise. 
HPLC method:  HPLC analysis using a linear gradient, at a flow rate of 1 mL/min was 
used with absorbance detection at 254 nm.  Solvent A is water, solvent B is 100 mM 
K2HPO4, pH 6.6 and solvent C is methanol: 0 min, 100% B; 5 min, 100 % B; 12 min, 48 
% A, 40 % B, 12 % C; 14 min, 50 % A, 30 % B, 20 % C; 18 min, 30 % A, 10% B, 60% 
C; 20 min, 100 % B; 25 min 100 % B.  The column used was a Supelcosil LC-18- T 
HPLC column (15 cm x 4.6 mm, 3 µM particle size). 
LC-MS method: Samples were analyzed by reverse-phase HPLC on an Agilent 1200 
HPLC system equipped with a diode array UV-Vis detector and a thermostatted 
autosampler (10 °C). The stationary phase was Supelcosil LC-18-T (15 cm × 3 mm, 3 
µm particles), maintained at 22 °C. The LC eluent consisted of a gradient of 75% 
methanol in 25% water with 5 mM ammonium acetate buffer, pH 6.6 (0.4 mL/min flow 
rate). The percentages of ammonium acetate buffer (B) and methanol (M) at time t varied 
according to the following scheme: {t,M,B}: {0,0,100}, {2,0,100}, {10,35,65}, 
{15,57.5,42.5}, {18,100,0}, {23,100,0}; {26,0,100}; {33,0,100}. Compounds were 
detected using absorbance at 254 nm. UV-Vis spectra (190 – 640 nm) were also 
collected and evaluated. Mass data were collected using an in-line Bruker Daltonics 
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micrOTOF-Q II ESI-Qq-TOF mass spectrometer (HyStar) in positive ion mode as 
indicated. 
 
Expression and purification of aminofutalosine synthase, MqnE: Escherichia coli 
M15 (pREP4) (Qiagen) harboring the pQE-30 vector containing the ttha0804 gene 
(obtained from Tohru Dairi lab) was grown aerobically for 12-15 h at 30 °C in 10 mL of 
LB
 medium  supplemented with 40 μg/mL kanamycin and 100 μg/mL ampicillin. This 
starter culture was added to 1.5 L of LB medium, supplemented with 40 μg/mL of 
kanamycin and 100 μg/mL of ampicillin. The cultures were grown aerobically (220 rpm) 
at 30 °C until the A600 was 0.5-0.6, at which point ferrous ammonium sulfate (100 mg/L) 
and l-cysteine (100 mg/L) were added. The cultures were then cooled to 4 °C and protein 
expression was induced by the addition of 100 µM of isopropyl-1-thio-β-d-
galactopyranoside (IPTG, LabScientific). The cultures were grown with slow shaking 
(110 rpm) at 15 °C for an additional ~ 18 h. and the cells were harvested by 
centrifugation at 6,300×g in a Beckman Coulter Avanti J-26 XPI with a JLA-8.1000 
rotor (15 min at 4 °C). The medium was discarded and the cell paste (~ 1.5 g per liter of 
cell culture) was stored submerged in liquid nitrogen until use. Protein purification was 
carried out in an anaerobic chamber (Coy Laboratories) containing 5% hydrogen and 
95% nitrogen. Cells were thawed and resuspended in 40 mL of Lysis Buffer (100 mM 
Tris-HCl, pH 7.5 at 25 °C) supplemented with 2 mM dl-dithiothreitol (DTT) and 10 mg 
of lysozyme. After 1.5 hours of incubation on ice with continuous stirring, the cells were 
further lysed by sonication, while stirring on ice, for 6 × 100 s using a Misonix Sonicator 
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XL-2000 (setting = 10). Cell debris was removed by centrifugation at 31,000×g in a 
Beckman Coulter Avanti J-E with a JA-17 rotor for 30 min at 4 °C and the supernatant 
was clarified through a 0.45 μm syringe filter. Aminofutalosine synthase was purified by 
nickel NTA affinity chromatography using a stepwise gradient of increasing imidazole 
concentration with two 5 mL HiTrap chelating HP column (GE Healthcare Life 
Sciences) arranged in tandem to attain a higher binding capacity and better retention 
efficiency of the protein of interest. The resin was charged with 2 column volumes (CV) 
of 0.1 M NiSO4, washed with 3 CV of filtered water to remove excess nickel, and 
equilibrated with 2 CV of Lysis Buffer supplemented with 2 mM. After loading the 
filtered protein sample, the resin was washed with 5 CV each of Wash Buffers (100 mM 
Tris-HCl, pH 7.5 at 25 °C, 300 mM NaCl, 1 mM DTT) containing 10 mM, 30 mM, and 
250 mM imidazole. Fractions of 0.5 mL were collected and analyzed for purity by 12% 
SDS-PAGE. His6-TTHA0804 (brownish color) eluted at 250 mM imidazole. Fractions 
containing the desired protein were pooled and the buffer was exchanged to Final Buffer 
(100 mM potassium phosphate, pH 7.5 at 25 °C, 2 mM DTT, 30% glycerol) via Econo-
Pac 10DG size exclusion chromatography (Bio-Rad). SDS-PAGE analysis showed the 
molecular weight of the protein as ~ 42.6 kDa (Figure S18). Typical yields were ~ 3.5 
mg per liter of cell culture. Proteins were stored submerged in liquid nitrogen. 
Characterization of aminofutalosine, 64: Each reaction mixture (150 µL) contained 
chemically or enzymatically synthesized 3-[(1-carboxyvinyl) oxy]-benzoic acid, 53 (2 
mM), S-adenosylmethionine, 66 (2 mM), purified MqnE (200 µM) and excess sodium 
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dithionite in 100 mM Tris-HCl buffer, pH 7.5. The reaction was allowed to proceed 
anaerobically for about 10 hrs. The reaction was repeated multiple times to give 
sufficient product for analysis. The reactions were quenched with an equal volume of 
8M guanidine hydrochloride and the protein was removed by ultrafiltration using 10 kDa 
centrifugal filters (Pall Life Sciences). Aminofutalosine was purified from the reaction 
mixture by HPLC (eluted at 20.2 minute) using the HPLC method mentioned previously. 
The compound was buffer exchanged into 5mM ammonium acetate by HPLC. The 
purified product was concentrated using a speedvac concentrator (Thermo Scientific), 
dissolved in D2O and characterized by 
1
H and 
13
C NMR (Figures 5.8, 5.9).
1
H NMR (500 MHz, D2O):  8.09 (t, J = 1.9 Hz, 1H), 8.02 (s, 1H), 7.96 (s, 1H), 7.88 (dt, 
 J = 7.9, 1.5 Hz, 1H), 7.59 (dt, J = 7.9, 1.5 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 5.80 (d, J = 
5 Hz, 1H), 4.85 (t, J = 5 Hz, 1H), 4.32 (t, J = 5 Hz, 1H), 4.14-4.19 (m, 1H), 2.96-3.11 
(m, 2H), 2.07-2.29 (m,2H). (Peaks from trace contaminant acetone in the sample also 
appears along with the f,f’ peaks of the compound, 64). 
13
C NMR (125 MHz, D2O): 204.5, 173.9, 155.3, 152.5, 148.6, 139.9, 136.3, 135.7, 
133.7, 129.9, 128.3, 128.27, 118.7, 87.4, 83.6, 72.9, 72.6, 34.2, 27.5. (Peak at 205 and 33 
ppm also comes from trace acetone contaminant in the sample).   
DEPT-135 
13
C NMR (Figure A11, AppendixA): 152.5 (CH), 139.9 (CH), 133.7 (CH),
129.9 (CH), 128.3 (CH), 128.27 (CH), 87.4 (CH), 83.6 (CH), 72.9 (CH), 72.6 (CH), 34.2 
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(CH2), 27.5 (CH2). The 2D NMR spectra (COSY and HSQC) of aminofutalosine 64 are 
shown in Figures 5.10 and 5.11 respectively. 
 
LC-MS analysis (ESI positive ion mode) of the TTHA0804 reaction mixture identified 
the new compound with m/z 414.14 [M+H]
+
 as aminofutalosine, 64 (theoretical m/z 
414.14) (Figure 5.12).  
 
Expression and purification of the aminofutalosine deaminase:  Escherichia coli TB1 
(NEB) harboring the pMAL-c2x vector containing the SCO5662 gene (obtained from 
Tohru Dairi lab) fused to the maltose binding protein 
162
 was grown aerobically for 12-
15 h at 37 °C in 20 mL of LB
 
medium supplemented with 100 μg/mL ampicillin. This 
starter culture (20 mL) was added to 2 L of LB medium supplemented with 100 μg/mL 
ampicillin. The cultures were grown aerobically with shaking (220 rpm) at 37 °C until 
the A600 was 0.6-0.7, at which point the cultures were cooled to 4 °C and protein 
expression was induced by the addition of 1 mM isopropyl-1-thio-β-d-galactopyranoside 
(IPTG, Lab Scientific). The cultures were grown with slow shaking (180 rpm) at 15 °C 
for an additional ~ 16 h. and the cells were harvested by centrifugation at 6,300×g in a 
Beckman Coulter Avanti J-26 XPI with a JLA-8.1000 rotor for 15 min at 4 °C. The 
medium was discarded and the cell paste (~ 2 g per liter of cell culture) was stored at -80 
°C until use. Protein purification was carried out using amylose resin affinity 
chromatography. Cells were thawed and resuspended in 20 mL of column Buffer (20 
mM Tris, 200 mM NaCl, 1 mM EDTA, pH 7.4 at 25 °C) supplemented with 20 mg of 
106 
lysozyme and 1 mM dl-dithiothreitol (DTT). Cells were further lysed by sonication 6 × 
30 s using a Misonix Sonicator 3000 (24 W, 1.5 s pulse, 1.5 s pause) and the cell debris 
was removed by centrifugation at 31,000×g in a Beckman Coulter Avanti J-E with a JA-
17 rotor for 45 min at 4 °C and the supernatant was clarified by passage through a 0.45 
μm syringe filter. Amylose resin (15 ml, NEB) was poured into a 2.5 x 10 cm column 
and the column was washed with 5 CV of column buffer. Then, the filtered crude lysate 
was loaded onto the column and allowed to flow under gravity. The column was washed 
with 6 CV of column buffer and the protein was eluted with 50 ml of the elution buffer 
(20 mM Tris, 200 mM NaCl, 1 mM EDTA, 10 mM maltose, pH 7.4) Fractions of 5 mL 
were collected and analyzed for purity by 12% SDS-PAGE. The fractions containing the 
desired protein were pooled and the buffer was exchanged to Final Buffer (100 mM 
Tris-HCl, pH 7.5 at 25 °C, 1 mM DTT, 30% glycerol) via Econo-Pac 10DG size 
exclusion chromatography (Bio-Rad). Protein concentrations were determined using the 
Bradford assay or A280 measurements. Factor Xa protease was used to cleave the maltose 
binding protein (MBP) from the deaminase at a w/w ratio of 1% the amount of fusion 
protein. The deaminase in the cleavage mixture was purified by anion exchange 
chromatography using HiTrap QFF (GE Life Sciences) as follows: The cleavage mixture 
was dialyzed against 20 mM sodium phosphate buffer, 25 mM NaCl, pH 5.5 for 4 hrs. 
The anion exchange column (5 mL) was washed with 3CV of the same buffer and the 
fusion protein cleavage mixture was loaded onto the column. The column flow through 
(1 mL fractions) was collected and the column was washed with 5CV of the same buffer. 
The flow through fractions were checked by A280 measurements and fractions 
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containing the deaminase were pooled and concentrated using a centrifugal filtering 
device with a 10 kDa MWCO membrane (Millipore) and the buffer was exchanged to 
Final Buffer (50 mM potassium phosphate, pH 7.5 at 4 °C, 150 mM KCl, 30% glycerol) 
via Econo-Pac 10DG size exclusion chromatography. SDS-PAGE analysis showed the 
molecular weight of SCO5662 as ~ 42.4 kDa (data not shown). Typical yields were ~ 20 
mg of protein per liter of cell culture. Proteins were stored at -80 °C. 
Expression and purification of the aminofutalosine nucleosidase: Escherichia coli 
TB1 (NEB) harboring the pMAL-c2x vector containing the hp0089 gene 
162
 (obtained
from Tohru Dairi lab) was grown aerobically for 12-15 h at 37 °C in 20 mL of LB
medium supplemented with 100 μg/mL ampicillin. This starter culture (20 mL) added to 
2 L of LB medium supplemented with 100 μg/mL ampicillin. The cultures were grown 
aerobically with shaking (220 rpm) at 37 °C until the A600 was 0.6-0.7, at which point 
the cultures were cooled to 4 °C and protein expression was induced by the addition of 1 
mM isopropyl-1-thio-β-d-galactopyranoside (IPTG, LabScientific). The cultures were 
grown with slow shaking (180 rpm) at 15 °C for an additional ~ 16 h. Cells were 
harvested by centrifugation at 6,300×g in a Beckman Coulter Avanti J-26 XPI with a 
JLA-8.1000 rotor for 15 min at 4 °C. The medium was discarded and the cell paste (~ 2 
g per liter of cell culture) was stored at -80 °C until use. Protein purification was carried 
out using amylose resin affinity chromatography. Cells were thawed and resuspended in 
20 mL of column Buffer (20 mM Tris, 200 mM NaCl, 1 mM EDTA, pH 7.4 at 25 °C) 
supplemented with 20 mg of lysozyme and 1 mM dl-dithiothreitol (DTT). Cells were 
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further lysed by sonication 6 × 30 s using a Misonix Sonicator 3000 (24 W, 1.5 s pulse, 
1.5 s pause) and the cell debris was removed by centrifugation at 31,000×g in a 
Beckman Coulter Avanti J-E with a JA-17 rotor for 45 min at 4 °C and the supernatant 
was clarified by passage through a 0.45 μm syringe filter. 15 ml of the amylose resin 
(NEB) was poured into a 2.5 x 10 cm column and the column was washed with 5 CV of 
column buffer. Then, the filtered crude lysate was loaded onto the column and allowed 
to flow under gravity. The column was washed with 6 CV of column buffer and the 
protein was eluted with 50 ml of the elution buffer (20 mM Tris, 200 mM NaCl, 1 mM 
EDTA, 10 mM maltose, pH 7.4) Fractions of 5 mL were collected and analyzed for 
purity by 12% SDS-PAGE. The fractions containing the glycosidase were pooled and 
the buffer was exchanged to Final Buffer (100 mM Tris-HCl, pH 7.5 at 25 °C, 1 mM 
DTT, 30% glycerol) via  Econo-Pac 10DG size exclusion chromatography (Bio-Rad). 
Protein concentrations were determined using the Bradford assay or A280 measurements. 
Factor Xa protease was used to cleave the maltose binding protein (MBP) from the 
glycosidase at a w/w ratio of 1% the amount of fusion protein. The glycosidase was 
purified by anion exchange chromatography using HiTrap QFF (GE Life Sciences) as 
described above. SDS-PAGE analysis showed the molecular weight to be ~25.2 kDa 
(data not shown). Typical yields were ~ 15-20 mg of protein per liter of cell culture. 
Proteins were stored at -80 °C. 
Analysis of the MqnE reaction mixture of bicarbonate and formate: The fate of the 
carboxyl group of 53 was determined using 
13
C-NMR. Potassium phosphate buffer (60
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mM, pH 8.6) in degassed water, was boiled for 30 min and then cooled and stored under 
a nitrogen atmosphere inside the anaerobic chamber until use. This prevented any 
contamination from atmospheric carbon dioxide. All reactions were carried out in this 
buffer in the anaerobic chamber. [U- 
13
C10] 3-[(1-carboxyvinyl) oxy]-benzoic acid was 
prepared by incubating [U- 
13
C10] chorismate (4 mM) with MqnA (500 µM) for 5 hrs. 
([U- 
13
C10] chorismate was isolated from a chorismate mutase deficient strain of 
Escherichia coli KA12 
177 
by feeding [U- 
13
C6] glucose according to the procedure 
described in Rieger et al
 150
. ) After removing MqnA by ultrafiltration, [U- 
13
C10] 3-[(1-
carboxyvinyl) oxy]-benzoic acid was incubated with MqnE (200 µM), SAM, 66 (2.5 
mM) and excess sodium dithionite for 12 hrs. Four control reactions were also set up 
lacking individual components. After removing MqnE by ultrafiltration, the reaction 
mixtures (150 µL) were transferred into 3 mm NMR tubes inside the anaerobic chamber, 
sealed with septa and parafilm and analyzed by 
13
C NMR on a Bruker Avance III 500 
MHz NMR instrument with a H-C-N Cryoprobe (
13
C 125 MHz). A new signal was 
detected at 160.01 ppm in the MqnE reaction containing all the components, which was 
not present in any of the control reactions (Figure 5.17). The chemical shift of the new 
signal matched exactly with a 
13
C sodium bicarbonate standard and the signal intensity 
also increased when spiked with an authentic sample of 
13
C bicarbonate. This suggests 
that CO2, trapped as bicarbonate in the basic reaction medium, is the most likely fate of 
the carboxyl group of 53. No NMR signal for formate was detected in any of the 
samples. 
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Iron content of the aminofutalosine synthase, MqnE: Iron content was analyzed as 
previously described. 
178
The following reagents were prepared: 8 M guanidine 
hydrochloride, 2 M HCl, 10 mM ferrozine in water (3-(2-Pyridyl)-5,6-diphenyl-1,2,4-
triazine-p,p’-disulfonic acid monosodium salt hydrate), 100 mM l-ascorbic acid in water  
and saturated ammonium acetate solution. To 100 µL of enzyme solution containing 0 to 
50 µM TTHA0804, 100 µL of 8 M guanidine hydrochloride and 100 µL of 2 M HCl 
were added and the solution was diluted to 550 µL. The resulting solution was 
centrifuged to remove any denatured protein. To 500 µL of the supernatant, 30 µL of the 
10 mM ferrozine solution and 30 µL of 100 mM freshly prepared L-ascorbic acid were 
added. The resulting solution was mixed thoroughly and incubated at RT for 30 min. 
The absorbance of the iron ferrozine complex was recorded at 562 nm using a Varian 
Cary Bio 300 UV-Visible Spectrophotometer (extinction coefficient for iron ferrozine 
complex is 27.9 mM
-1
cm
-1
). The iron content was determined by comparing this reading
to a standard curve that was generated under identical conditions using Fe (NH4)2(SO4)2 
with a concentration range from 0 to 100 µM. 
Sulfide content of the aminofutalosine synthase, MqnE: Sulfide content was analyzed 
using the methylene blue assay. 
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 To 300 µL of assay solution containing 0 to 50 µM
TTHA0804, 1 ml of 1% (w/v) zinc acetate was added followed by 50 µL of 3 M NaOH. 
This mixture was agitated gently and 250 µL of 0.1 % N,N-dimethyl-p-
phenylenediamine (DMPD) monohydrochloride in 5 M HCl and 50 µL  of 23 mM FeCl3 
in 1.2 M HCl were added. The resulting solution was mixed vigorously after each 5 min 
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intervals over a 30 min time period. The samples were then centrifuged at 16,110×g in 
an Eppendorf 5415 R with a F45-24-11 rotor for 5 min at 25 °C. The supernatant was 
collected and the absorbance at 670 nm was recorded using a Varian Cary Bio 300 UV-
Visible Spectrophotometer. The sulfide content was determined by comparing this 
reading to a standard curve that was generated under identical conditions using a fresh 
solution of sodium sulfide (Na2S; Fisher Scientific) in 0.1 M NaOH with a concentration 
range from 0 to 100 µM. 
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CHAPTER VI 
MENAQUINONE BIOSYNTHESIS: MECHANISTIC STUDIES ON THE 
RADICAL SAM ENZYME, MqnE
# 
Introduction 
Menaquinone (26, vitamin K) is a lipid-soluble molecule that shuttles electrons between 
membrane-bound redox enzymes in the bacterial respiratory chain.
75 
It is also a very
important vitamin in mammals where it participates as a cosubstrate in the carboxylation 
of glutamic acid residues in various proteins involved in blood coagulation
110
 and bone
morphogenesis
111
. Various steps of the alternative menaquinone biosynthetic pathway
are reconstituted in vitro.
123,142,144,147
The pathway begins (Figure 6.1) with  MqnA
(SCO4506) catalyzing  the transformation of  chorismate, 39 into 3-[(1-carboxyvinyl) 
oxy]-benzoic acid, 53 and then the radical SAM enzyme MqnE (SCO4494) catalyzes the 
transformation of the latter into aminofutalosine 64 in  the presence of S-
adenosylmethionine (SAM) and dithionite.
147
 Aminofutalosine is then converted to
compound 50 by aminofutalosine hydrolase (MqnB, SCO4327) or by a combination of 
aminofutalosine deaminase (SCO5662) and MqnB
142,162
. Cyclization of 50 by another
radical SAM enzyme MqnC (SCO4550) gives compound 51 
144
 which is then converted
to 5, 8-dihydroxy-2-naphthoic acid 52 by MqnD (SCO4326).
123
 Bioinformatics studies
suggests that 52 is converted to menaquinone 26 in S. coelicolor A3(2) in several 
tailoring reactions catalyzed by SCO4491 (prenylation), SCO4556 (methylation), and 
SCO4490 or SCO4492 (decarboxylation)(Figure 6.1).
123 
#
(Nilkamal Mahanta carried out all the biochemical studies reported here. Dmytro Fedoseyenko 
synthesized compounds 83, 88, 96, 101a, 101b, 101c, 109, 114, 117,118) 
______
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Figure 6.1: Aminofutalosine dependent pathway for the biosynthesis of menaquinone. 
One of the most interesting enzymes on this pathway, MqnE catalyzes the addition of 5’-
deoxyadenosyl radical to the enol ether double bond of 3-[(1-carboxyvinyl) oxy]-
benzoic acid 53 to finally yield aminofutalosine 64. It represents a unique catalytic motif 
in radical SAM enzymology, where all previously reported radical SAM enzymes
164-168
use the 5’-deoxyadenosyl radical to abstract a hydrogen atom from the substrate or from 
the active site glycine residue to carry out the radical mediated transformations. A 
mechanism for the MqnE catalyzed reaction has been proposed (Figure 6.2).
147 
Various
biochemical experiments that are performed to test our mechanistic proposal are 
described in this chapter. 
114 
Figure 6.2: Mechanistic proposal for the MqnE catalyzed reaction. 
Results and discussion 
Mechanistic studies: We have previously proposed a mechanism for the MqnE 
catalyzed reaction (Figure 6.2). In this proposal, addition of the radical 67 to the vinyl 
double bond of compound 53 gives the captodative radical 69. Rearrangement of this 
radical via 70 gives 71. Decarboxylation of 71, facilitated by the alkoxy radical, gives 
72. A final electron transfer from 72 to the [4Fe-4S]
2+
 cluster completes the formation of
64. In this study, we have used different substrate analogs to trap intermediate radical
species to provide support for the various steps of the mechanism. 
Trapping of the captodative radical 69: To probe the first step of the mechanistic 
proposal (Figure 6.2), a substrate analog 83 was synthesized (Scheme 6.1) in which the 
oxygen in substrate 53 is replaced with a methylene group. To test whether compound 
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83 is a substrate, MqnE (100 uM) was incubated with compound 83 (1.5 mM) 
anaerobically in the presence of SAM (2 mM) and excess sodium dithionite. After 10 
hrs., the reaction was quenched with 8M guanidine hydrochloride, the protein was 
removed by ultrafiltration and the reaction mixture was analyzed by reverse phase 
HPLC. This analysis showed the formation of a new compound at 19.3 min in the HPLC 
chromatogram (Figure 6.3) which was identified as compound 84 by NMR spectroscopy 
(Figures B5-B10, Appendix B)  and MS spectrometry (Figure 6.4). Formation of this 
compound was not observed in any of the control reactions. Moreover, formation of 5’-
deoxyadenosine was also not observed in the HPLC analysis of the full reaction mixture. 
 
Synthesis of compound 83: Compound 83 was synthesized using the scheme shown 
below:  
 
Scheme 6.1: Synthetic scheme for compound 83 
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Figure 6.3: HPLC analysis of the MqnE reaction mixture with substrate analog 83.  
[Blue trace: chromatogram of the full reaction mixture (MqnE + 83+ SAM+ dithionite). 
Red trace: chromatogram of the control reaction mixture lacking 83. Uncoupled 
production of 5’-deoxyadenosine was observed at 19.5 min in this control reaction. 
Green trace: chromatogram of the control reaction mixture lacking MqnE. No signal at 
19.3 min was observed in control reactions individually lacking SAM or dithionite (data 
not shown). The inset shows the structure of the product 84]. 
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Figure 6.4:  LC-MS analysis of the MqnE reaction mixture with substrate analog 83.  
[In the mass spectrum, m/z 458.1672, [M+H]
+
 corresponds to compound 84 (theoretical
m/z 458.1670) and m/z 136.0616 corresponds to adenine derived from aminofutalosine 
(theoretical m/z 136.0620)] 
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Formation of compound 84 suggested the addition of 5’-deoxyadenosyl radical to the 
vinyl double bond of 83 to yield the radical intermediate 85, which upon abstraction of a 
hydrogen atom, led to the formation of compound 84 (Figure 6.5). 
 
 
Figure 6.5: Mechanistic proposal for formation of compound 84. 
 
When MqnE reaction was run using 83 as substrate in deuterated buffer, incorporation of 
deuterium was observed into 84 (Figure B11, Appendix B) suggesting that the hydrogen 
is probably derived from a buffer component or from an exchangeable amino acid 
residue in the active site. Moreover, analysis of MqnE by intact protein mass 
spectrometry did not detect any change in the mass of the enzyme after the reaction 
which rules out any enzyme-substrate covalent adduct formation (data not shown). 
Analysis of MqnE after the reaction with 83 by SDS-PAGE (Figure B12, Appendix B) 
failed to detect any degradation of the enzyme suggesting that radical 85 probably does 
not abstract a hydrogen atom from the α- carbon of the backbone peptide which, in turn, 
may lead to a radical mediated cleavage of the backbone altering the mass of the protein. 
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We provide two possible mechanistic explanations for the formation of compound 84. 
First, we propose that replacing the bridging oxygen of 53 with a methylene group as in 
83 might slow down the decarboxylation of radical 87 significantly (Figure 6.6) as it 
would yield a less stable alkene radical anion as compared to a stable ketyl radical anion 
72 (Figure 6.2) when 53 is used as the substrate. In such as case, the carboxyl stabilized 
radical 85 which probably has the highest concentration in this equilibrium (Figure 6.6) 
would capture a hydrogen atom to give 84. The turn over number is close to one. 
 
Secondly, since ring opening of the epoxide radical 70 (Figure 6.2) is likely to be 
accelerated by acid catalysis, we believe that substituting the bridging oxygen of 53 with 
a carbon might block the rearrangement of the radical 85 to radical 87 through the spiro 
intermediate 86 as it cannot undergo acid catalyzed ring opening (Figure 6.6). Radical 85 
would ultimately capture a hydrogen atom to yield compound 84. However, a crystal 
structure of MqnE bound with 53 or 83 would be required to support this hypothesis. 
Identification of compound 84 provides evidence for the first step of the MqnE reaction 
mechanism, where 5’-deoxyadenosyl radical is shown to be involved in a radical 
addition reaction with the substrate in radical SAM enzymology. 
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Figure 6.6: Probable mechanism for the formation of compound 84. 
 
Alternate strategy for trapping the captodative radical 69: As an alternative strategy to 
trap the captodative radical 69 proposed in the mechanism (Figure 6.2), another substrate 
analog 88 was designed and synthesized in which a halogen group (Br) was introduced 
in the vinyl double bond terminus of the substrate 53 (Scheme 6.2). 
 
Carbon halogen bonds, beta to a radical center are known to undergo very rapid 
fragmentation reactions (C-Br kcleavage = 3x10
8
s
-1
)
180, 181
. Hence using 88 as the substrate 
might help in trapping the captodative radical as compound 90 after the loss of the 
bromine radical which would also serve as a mechanistic evidence for the 5’-
deoxyadenosyl radical addition step in the MqnE catalyzed reaction (Figure 6.7).
147
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Synthesis of compound 88: Compound 88 was synthesized using the scheme shown 
below. 
Scheme 6.2: Synthetic scheme for substrate analog 88 
Figure 6.7: Mechanistic proposal for trapping the captodative radical 89. 
To test this hypothesis, MqnE (100 uM) was incubated with compound 88 (2 mM) 
anaerobically in the presence of SAM (2 mM) and excess sodium dithionite. After 10 
hrs., the reaction was quenched with 8M guanidine hydrochloride, the protein was 
removed by ultrafiltration and the reaction mixture was analyzed by reverse phase 
HPLC. This analysis showed the formation of a new compound at 17.6 min in the HPLC 
121 
chromatogram (Figure 6.8) which was identified as compound 90 by 1D and 2D NMR 
spectroscopy (Figures 6.9-6.13) and MS spectrometry (Figure 6.14). This compound has 
resulted from the cleavage of the C-Br bond beta to the radical center in 89 generated by 
the addition of 5’-deoxyadenosyl radical to the enol ether double bond of the compound 
88 (Figure 6.6). This observation is consistent with our mechanistic proposal (Figure 
6.2) where the addition of the 5’-deoxyadenosyl radical on the substrate has been 
implicated in the formation of C-C bond in the product. 
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Figure 6.8: HPLC analysis of the MqnE reaction mixture with compound 88 (A).  
[Blue trace: chromatogram of the full reaction mixture (MqnE + 88+ SAM+ dithionite). 
Red trace: chromatogram of the control reaction mixture lacking 88. Green trace: 
chromatogram of the control reaction mixture lacking MqnE. No signal at 17.6 min was 
observed in control reactions individually lacking SAM or dithionite (data not shown). 
The inset shows the structure of the identified reaction product 90 which was 
characterized by 1D and 2D NMR (Figures 6.9-6.13) and MS analysis (Figure 6.14)]. 
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NMR and MS characterization of compound 90: 
 
 
Figure 6.9: 
1
H NMR (500 MHz, D2O) spectrum of compound 90. 
 
Figure 6.10: 
13
C NMR (125 MHz, D2O) spectrum of compound 90. 
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Figure 6.11: 
13
C DEPT-135 NMR (125 MHz, D2O) spectrum of compound 90 
 
 
 
Figure 6.12: 
1
H-COSY spectrum of compound 90. 
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Figure 6.13: HSQC spectrum of compound 90. 
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Figure 6.14:  LC-MS (ESI, positive ion mode) analysis of compound 90. 
[In the mass spectrum, m/z 458.1312, [M+H]
+
 corresponds to compound 90 (theoretical
m/z 458.1314)]. 
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Careful observation of the HPLC chromatogram led to the finding of another new 
product in the reaction mixture in low intensity at 19.25 min (Figure 6.15) which was 
identified to be aminofutalosine 64 by NMR and MS analysis.
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Figure 6.15: HPLC analysis of the MqnE reaction mixture with compound 88 (B). [Blue 
trace: chromatogram of the full reaction mixture (MqnE + 88+ SAM+ dithionite). Red 
trace: chromatogram of the control reaction mixture lacking 88. Green trace: 
chromatogram of the control reaction mixture lacking MqnE. No signal at 19.2 min was 
observed in control reactions individually lacking SAM or dithionite (data not shown). 
The inset shows the structure of aminofutalosine 64 characterized before (Chapter V)]. 
 
Observation of the formation of aminofutalosine in this reaction was mechanistically 
intriguing. We propose that aminofutalosine, 64 might have resulted from the 
captodative radical intermediate 89 via the spirocylization reaction which seems to be in 
competition with the beta scission reaction as mentioned above (Figure 6.7) suggesting 
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that the spirocyclization reaction is considerably faster. A mechanistic proposal for the 
formation of aminofutalosine, 64 from substrate analog 88 is outlined in Figure 6.16. 
Addition of 5’-deoxyadenosyl radical 67 to substrate analog 88 generates the captodative 
radical 89 which rearranges through the spirocyclic radical 91 to give radical 92. Radical 
92 loses carbon dioxide to generate 93 which upon loss of a bromine radical followed by 
protonation yields aminofutalosine, 64. 
 
Figure 6.16: Mechanistic proposal for the formation of aminofutalosine 64. 
Alternate mechanistic proposals for MqnE:  In our study, we also considered two 
alternate mechanistic possibilities for the MqnE catalyzed reaction. In mechanism A 
(Figure 6.17), oxidation of 69 to the oxocarbenium ion 69a would be followed by 
electrophilic addition to the benzene ring to generate the intermediate 69b. However, 
this mechanism seems unlikely because subsequent epoxide ring opening in 69b would 
generate a high energy two-electron deficient oxene intermediate.  We propose addition 
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of an electron will convert 69b to spirocyclic radical 70 which will then proceed as 
proposed (Figure 6.2). In mechanism B, a high energy aryl radical 94 is proposed to be 
formed from the captodative radical 69 on cleaving the C-O bond by beta scission. This 
is followed by radical addition from 94 onto the carbonyl group of the intermediate 95 to 
form the alkoxy radical 71 which loses carbon dioxide and an electron to form 
aminofutalosine 64 (Figure 6.17). 
 
Figure 6.17: Alternate mechanistic proposals for the MqnE catalyzed reaction. 
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Measurement of substituent effects on the radical addition to benzene ring: In this 
alternative strategy for the captodative radical trapping, observation of these two 
competing reactions with substrate analog 88 provided us with an opportunity to gain 
further mechanistic insights to determine the most probable mechanism. As it was clear 
from this experiment that the spirocyclization reaction is surprisingly rapid, hence using 
the radical trap incorporated at the double bond terminus of the substrate, substituent 
effects on the radical addition to the benzene ring could be determined. If the 
spirocyclization is occurring as proposed (Figure 6.2), then radical stabilizing 
substituents at the sites of high spin density of 70 would accelerate the rate of 
spirocyclization while substituents at positions of low spin density would have a smaller 
effect. Moreover, since in our system, the partitioning of 89 between spirocyclization 
and radical trapping is primarily influenced by the competition between bromine atom 
loss and the radical addition to the benzene ring, hence the binding effects arising from 
the substitution is likely to cancel out. Substituting the benzoic acid ring at carbons 4 
and/or 6 positions with hetero atom containing substituents such as amino / hydroxyl or 
fluoride group in compound 88 should accelerate the spirocyclization because these 
groups are known to stabilize radicals
182-184
. This effect could be explained by a 
stabilizing two center-three electron interaction between the singly occupied orbital on 
carbon of the radical center and nonbonding electrons on nitrogen, oxygen or fluoride
182, 
183
. Hence, in order to probe the proposed radical rearrangement through the spirocyclic 
intermediate, amino and fluoro substituted substrate analogs (Figure 6.18) were 
synthesized (Scheme B1, Appendix B). Observation of substituent effects on the 
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spirocyclization step will be consistent for the proposed mechanism of MqnE (Figure 
6.2) and will not support the mechanism B through the intermediacy of a highly 
energetic aryl radical intermediate  94 (Benzene C-H bond dissociation energy = 472 
kJ/mol, Figure 6.16).
185 
 
 
Figure 6.18: Substituted substrate analogs for MqnE 
When substrate analog 96 was used in the MqnE catalyzed reaction, (1.5 mM substrate 
analog, 2mM SAM, 100 µM MqnE and excess dithionite) formation of two compounds 
were observed in the HPLC chromatogram which were absent in the control reactions (at 
16.5 min and 19.8 min, Figures 6.19 and 6.21). Compounds 98 and 100 formed in this 
reaction were characterized by 1D and 2D NMR spectroscopy (Figures B13-B17 and 
B18- B20 Appendix B, respectivley) and mass spectrometry (Figure 6.20 and Figure 
6.22). Compound 98 (Figure 6.19) resulted from the C-Br bond cleavage radical clock 
reaction (defined by ktrap, Figure 6.23) while compound 100 (Figure 6.21) resulted from 
the spirocylization reaction (defined by kspiro, Figure 6.23). By using the relation kspiro = 
ktrap ([100] / [98]), we can determine the relative rate of spirocyclization and hence the 
effect of the NH2 substituent on the radical addition step (Figure 6.23). 
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Figure 6.19: HPLC analysis of the MqnE reaction mixture using compound 96 (A). 
[Blue trace: chromatogram of the full reaction mixture (MqnE + 96+ SAM+ dithionite). 
Red trace: chromatogram of the control reaction mixture lacking 96. Green trace: 
chromatogram of the control reaction mixture lacking MqnE. The inset shows the 
structure of identified reaction product 98]. 
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Figure 6.20:  LC-MS (ESI, positive ion mode) analysis of compound 98. [In the mass 
spectrum, m/z 473.1422, [M+H]
+
 corresponds to compound 98 (theoretical m/z 
473.1423)]  
 
 131 
 
 
-100
400
900
1400
1900
2400
2900
19.3 19.5 19.7 19.9 20.1 20.3
A
b
s 
2
5
4
 n
m
 (
m
A
u
)
Retention time (min)
Compound 96 + MqnE +
SAM + dithionite
No substrate
No MqnE
 
Figure 6.21: HPLC analysis of the MqnE reaction mixture using compound 96 (B). 
[Blue trace: chromatogram of the full reaction mixture (MqnE + 96+ SAM+ dithionite). 
Red trace: chromatogram of the control reaction mixture lacking 96. Green trace: 
chromatogram of the control reaction mixture lacking MqnE. The inset shows the 
structure of the identified reaction product 100]. 
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Figure 6.22: LC-MS (ESI, positive ion mode) analysis of compound 100. [In the mass 
spectrum, m/z 429.1526, [M+H]
+
 corresponds to compound 100 (theoretical m/z 
429.1524)]. 
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Figure 6.23: Substituent effects measurement using substrate analog 96. 
Compounds 98 and 100 produced in the reaction mixture were purified using reverse 
phase HPLC and treated separately with 5M hydrochloric acid and heated at 90°C for 3-
4 hrs in order to release adenine. Each acid treated sample was neutralized and analyzed 
immediately using HPLC. The amount of adenine formed from each compound was 
determined based on a standard curve of adenine (Figure B21, Appendix B). Then the 
ratio [100]/ [98] (Figure 6.22) was calculated for substrate analog 96 based on the 
amounts of adenine formed (directly proportional to the amounts of 98 and 100) to give 
an estimate of the effect of the amino substituent on the radical addition step (Table 6.1).             
Formation of two compounds of similar structure as that of 98 (103a, 103b, 103c) and 
100 (105a, 105b, 105c) were also observed (Figure 6.24) when fluoro substituted 
compounds 101a, 101b and 101c (Figure 6.18) were used as substrates in the MqnE 
reaction. These compounds were analyzed by HPLC and characterized by 1D and 2D 
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NMR and mass spectrometry [Figures B22-B24 (103a), B25-B27 (103b), B28-B33 
(103c), B34-B38 (105a), B39-B43 (105b), and B44-B49 (105c) Appendix B]. 
 
Figure 6.24: Substituent effects measurement using substrate analogs 101(a,b,c). 
 
Similar experiments were performed for the quantification of the final compounds 
formed from each of the fluoro substituted substrate analogs (Figure 6.24) and the 
product ratio ([105a]/ [103a], [105b]/ [103b], ([105c]/ [103c]) in each case was 
determined using the method described above. Compounds 90 and 64 formed when 
substrate analog 88 was used as the substrate (Figures 6.8 and 6.15) were also quantified 
in a similar manner. Thereafter, the ratios of the compounds formed for the substituted 
substrate analogs were compared with the ratio of [64]/ [90] for the analogue 88 in order 
to determine a relative rate of spirocyclization and hence the effect of substituents on the 
step involving radical addition to the benzene ring (Figure 6.25 and Table 6.1). 
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Figure 6.25: Substituent effects measurement in the MqnE reaction 
Table 6.1: Ratio of the two compounds formed in the MqnE reaction  
 
Substrate analog   [kspiro]/[ktrap] Relative ratio 
88 0.11 ± 0.02 1 
96 0.89 ± 0.04 8.1 
101a 0.45 ± 0.03 4.1 
101b 0.22 ± 0.02 2.0 
101c 0.42 ± 0.05 3.8 
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It is evident from these results that the presence of the radical stabilizing amino 
substituent (analogue 96) at the site of high spin density of 99 accelerates the 
spirocyclization (Figure 6.23) as compared to the unsubstituted analog 88 (indicated by 
about 8 times larger ratio of [kspiro]/[ktrap]). On the other hand, presence of lesser radical 
stabilizing fluoride substituents at 4 and/or 6 positions (analogs 101a and 101c) in the 
aromatic ring have a relatively lower relative rate of spirocyclization with respect to the 
unsubstituted analog 88 (about 4 times).The substrate analog with the fluoride 
substituent at position 5 in the ring (analog 101b) has even smaller effect. These results 
indicated that transient radical character at 4 and/or 6 positions in the aromatic ring of 
the substrate during the MqnE catalytic cycle is more stabilized by the presence of 
hetero atom containing substituents at these positions (Figure 6.25).
182-184
 The relative 
ratio of spirocyclization was also found to be independent of the time of the reaction. 
These substituent effect measurements suggested that radical addition to the benzene 
ring during the rearrangement of the captodative radical 69 to alkoxy radical 71 via the 
spirocyclic radical intermediate 70 is the most probable mechanistic route for MqnE 
(Figure 6.2). Observation of these substituent effects also rules out an alternate 
mechanistic proposal (Figure 6.17) via a highly energetic aryl radical intermediate in 
which such an effect would not have been observed. 
Trapping of the alkoxy radical 71: Another important insight for the mechanistic 
proposal for MqnE could be obtained from characterization of the alkoxy radical 71 
formed after the rearrangement of the captodative radical via the spirocyclic radical 
intermediate (Figure 6.2). In order to trap the alkoxy radical 71, a substrate analog 109 
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was synthesized (Scheme 6.3) in which the carboxyl group of the pyruvic side chain of 
the substrate 53 is replaced with an amide group. Replacingt the carboxyl group of the 
substrate by the amide group should block the decarboxylation reaction (Figure 6.26) 
because isocyanic acid resulting from removal of the amide group is much less stable 
than the released carbon dioxide as proposed before (Figure 6.2). This is expected to 
lead to the formation of compound 113 from the alkoxy radical intermediate 112 on 
abstraction of hydrogen from solvent or from an active site residue (Figure 6.26). 
Detection of compound 113 in the reaction mixture would be consistent with the 
intermediacy of radical 71 in the proposed mechanism of MqnE (Figure 6.2). 
Synthesis of compound 109: Compound 109 was synthesized using the scheme shown 
below. 
 
Scheme 6.3: Synthetic scheme for the substrate analog 109 
 
 137 
 
 
To test this hypothesis, compound 109 was used as a substrate in the MqnE reaction 
using flavodoxin (FldA) / flavodoxin reductase (FldR) as the reductant system ([MqnE] 
= 100 uM, [SAM]= 2 mM, [compound 109]= 1 mM, [Flavodoxin]= [Flavodoxin 
reductase]= 50 uM, [NADPH]= 2 mM). The reaction was allowed to proceed for about 
8hrs, and the protein was removed by ultracentrifugation after quenching. The reaction 
mixture was analyzed by HPLC and LC-MS. 
 
Figure 6.26: Trapping the alkoxy radical 112 using the amide substrate analog, 109. 
In the LC-MS chromatogram, formation of a new compound was observed in the full 
reaction (Figure 6.27) which was absent in the control reactions. From the MS spectrum 
(Figure 6.28) and MS/MS spectrum, the new compound formed was determined to be 
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113 as predicted above (Figure 6.26). However, comparison with an authentic reference 
compound would be required to confirm its identity. Currently, synthesis of 113 is in 
progress. Moreover, formation of aminofutalosine 64 was not observed in the reaction 
mixture suggesting that isocyanic acid is not released from radical 112 (Figure 6.26). 
The trapping of the alkoxy radical 112 is as compound 113 is consistent with the 
intermediacy of radical 71 in our mechanistic proposal for MqnE. 
 
12.4 12.6 12.8 13.0 13.2 13.4 Time [min]
0
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4000
6000
Intens.
AMIDE analog f ull rxn NO DTT _1-A,3_01_10065.d: EIC 459.1630±0.2 +All MS no FldA_1-A,7_01_10069.d: EIC 459.1630±0.2 +All MS no FldR_1-A,8_01_10070.d: EIC 459.1630±0.2 +All MS
no MqnE_1-A,6_01_10068.d: EIC 459.1630±0.2 +All MS no NADPH_1-B,1_01_10072.d: EIC 459.1630±0.2 +All MS no SAM_1-A,9_01_10071.d: EIC 459.1630±0.2 +All MS
no substrte_1-A,5_01_10067.d: EIC 459.1630±0.2 +All MS  
Figure 6.27: LCMS analysis of the MqnE reaction mixture using compound 109. [(EIC: 
459.163 m/z) Red trace: chromatogram of the full reaction mixture (MqnE + 109+ 
SAM+ FldA + FldR + NADPH). No signal at 12.7 min was observed in control 
reactions individually lacking substrate 109, MqnE, SAM, FldA, FldR or NADPH (other 
traces). The inset shows the structure of the identified reaction product 113 which was 
characterized by MS analysis]. 
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Figure 6.28:  LC-MS (ESI, positive ion mode) analysis of compound 113. [In the mass 
spectrum, m/z 459.1624, [M+H]
+
 corresponds to compound 113 (theoretical m/z 
459.1630)]. 
 
So far, we have been able to trap the captodative radical 69 and the alkoxy radical 71 
(Figure 6.2) using substrate analog based mechanistic strategy. Moreover, observation of 
substituent effects on the step involving radical addition to the aryl ring also suggest the 
intermediacy of the proposed spirocyclic radical intermediate 70. A structure of MqnE 
with the substrate 53 or a substrate analogue bound at the active site would be required 
to understand whether our proposal is consistent with the stereo-electronic requirements 
of the spirocyclization reaction. Currently, structural studies on MqnE are in progress in 
collaboration with Juan Fontecilla group, IBS, Grenoble, France. 
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A new reaction of MqnE: An additional activity of MqnE was observed when 114 was 
used as substrate analogue. Substrate analog 114 was synthesized (Scheme 6.4) in which 
the vinyl double bond of the substrate 53 is replaced with a methyl group. 
 
 
Scheme 6.4: Synthetic scheme for compound 114 
Analog 114 was used as a substrate in the MqnE reaction ([MqnE] = 100 uM, [SAM] = 
2 mM, [compound 114] = 1.5 mM, dithionite in excess). Protein was removed by 
ultracentrifugation and the reaction mixture was analyzed by HPLC and LCMS methods. 
From the analysis of the reaction mixture, formation of two new compounds was 
observed as suggested by the appearance of two new signals at 17.4 min and 19.4 min in 
the HPLC chromatogram (Figure 6.29). The compound eluting at 16 min was identified 
to be compound 117 (Figure 6.28) from mass spectrometric studies (Figure 6.30 and co-
elution with a reference compound (Figures B50-B52, Scheme B2, Appendix B) and the 
compound eluting at 19.4 min was identified to be 5’-deoxyadenosine, 116 (Figure 6.28) 
by mass spectrometric analysis (Figure 6.31) and comparing with a reference standard 
(Figure B53, Appendix B). 
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Figure 6.29: HPLC analysis of the MqnE reaction mixture using compound 114. [Blue 
trace: chromatogram of the full reaction mixture (MqnE + 114 + SAM+ dithionite). 
Formation of both 117 and 5’-deoxyadenosine, 116 were observed at 17.4 min and 19.4 
min respectively. Red trace: chromatogram of the control reaction mixture lacking 114. 
Uncoupled formation 5’-deoxyadenosine was observed at 19.4 min. Green trace: 
chromatogram of the control reaction mixture lacking MqnE. No signals at 17.4 min and 
19.4 min were observed in control reactions individually lacking SAM or dithionite (data 
not shown). The inset shows the structure of the identified reaction products 117 and 5’-
deoxyadenosine 116] 
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Figure 6.30: LC-MS (ESI, positive ion mode) analysis of compound 117. [In the mass 
spectrum, m/z 165.0547, [M+H]
+
 corresponds to compound 117 (theoretical m/z 
165.0546)]. 
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Figure 6.31: LC-MS (ESI, positive ion mode) analysis of compound 116. [In the mass 
spectrum, m/z 252.1090, [M+H]
+
 corresponds to 5’-deoxyadenosine, 116 (theoretical 
m/z 252.1091) and m/z 136.06 corresponds to adenine derived from 116 (theoretical m/z 
136.06)]. 
 
Formation of these compounds can be described as shown in the mechanistic proposal 
(Figure 6.32). 5’-deoxyadenosyl radical, 67 abstracts a hydrogen atom from the methyl 
group of 114 to generate 5’-deoxyadenosine 116 and radical 115 which upon 
decarboxylation and oxidation gives compound 117. This observation suggested that 
when the vinyl group of the substrate is absent, instead of the radical addition, the 5’-
deoxyadenosyl radical 67 is able to abstract a hydrogen atom from the methyl group of 
the substrate, a mode of reactivity observed for almost all the reported radical SAM 
enzymes
163-167
. This is a new activity observed for MqnE and it probably indicates that 
the hydrogen abstraction capability by the reactive 5’-deoxyadenosyl radical from 
substrate or protein active site amino acid residue is inherent in radical SAM enzymes; 
however, in some instances they evolve to function differently as observed in the MqnE 
reaction in menaquinone biosynthesis.
147 
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Figure 6.32: Mechanistic proposal for the formation of 117. 
An important aspect of the MqnE reaction is the facial selectivity of the addition of 5’-
deoxyadenosyl radical 67 on the double bond of substrate 53 to generate the captodative 
radical 69 (Figure 6.2). Since the methyl group of 114 must be pointing at the 5’-
deoxyadenosyl radical 67 for hydrogen abstraction to occur, hence identifying the 
correct enantiomer of 114 that is the substrate for MqnE might tell us about the facial 
selectivity of the adenosyl radical addition on the double bond in the native reaction. The 
stereochemical experiment is described in Appendix B (Figures B54- B58). 
Currently studies are in progress to obtain further stereochemical information in the 
radical addition step in the MqnE reaction. However, experiments using substrate 
analogs with a constrained double bond would be required to determine the correct 
conformation of the bound substrate in the active site. This stereochemical information 
would facilitate our structural studies with MqnE, particularly in modelling studies if the 
resolution of the structure is low or suitable substrate/SAM bound crystal structure of 
MqnE is not obtained. 
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Inhibition studies on MqnE: Several human pathogenic organisms such as Helicobacter 
pylori (causes gastric carcinoma), Campylobacter jejuni (causes gastroenteritis), 
Chlamydia (causes urethritis and respiratory tract infections), Spirochetes (causes 
syphilis / Lyme disease) synthesize menaquinone by the alternative pathway.
123,141
 
Moreover, this pathway is absent in humans and commensal intestinal bacterial 
species.
123
 Hence the inhibitors and antibiotics targeting the enzymes on this pathway 
could prevent the growth of several important human pathogens without damaging the 
intestinal bacterial flora. In the hunt for suitable chemotherapeutics against these 
pathogenic organisms, previous attempts have been made to find a suitable inhibitor for 
this pathway.
145
 It was found that branched chain fatty acids inhibit the biosynthesis of 
menaquinone in H.pylori and the most probable enzyme target was predicted to be the 
prenyl transferase enzyme involved in the latter steps of the biosynthetic pathway.
145 
We found that on incubation of MqnE (100 µM) with compound 83 (1.5 mM) for about 
an hour, the enzyme almost completely lost its activity as the activity was not recovered 
on addition of the native substrate 53 (1.5 mM), SAM (2 mM) and dithionite (Figure 
6.33). We previously reported that in MqnE catalyzed reaction, compound 83 is 
converted to 84 (Figure 6.3). 
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Figure 6.33: HPLC analysis of the MqnE reaction mixture showing inhibition. [Blue 
trace: chromatogram of the full reaction mixture (MqnE + 53 + SAM+ dithionite). 
Formation of aminofutalosine was observed at 20.2 min. Red trace: chromatogram of the 
reaction mixture using MqnE preincubated with compound 83, followed by addition of 
substrate 53, SAM and dithionite. Formation of aminofutalosine was not observed. 
MqnE retained about 5% of the activity when a 1:1 mixture of 53 and 83 was used as the 
substrate mixture (data not shown). Green trace: chromatogram of the control reaction 
mixture lacking MqnE]. 
 
We predict that this could be an irreversible mechanism based inactivation
186, 187
 of the 
enzyme wherein tight binding of compound 84, a reaction intermediate analogue and a 
bisubstrate analogue formed in the reaction coordinate of 83 may inactivate the enzyme. 
This renders the enzyme unable to bind the native substrate and hence loses its activity. 
However, a structure of MqnE with the substrate analog 83 bound at the active site 
would be required to clarify this assumption and provide the mechanistic insight for the 
observed inhibition of MqnE. No other substrate analogs (such as 88 and 114) were 
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observed to exhibit such an inhibitory activity when incubated with MqnE (Figure B59, 
Appendix B). 
A simple kinetic model could be put forward for this type of irreversible inhibition.
186 
The inactivator initially forms a reversible enzyme-inhibitor (E-I) complex defined by 
the binding constant KI, followed by the transformation of the inactivator to a different 
form (I’) still bound to the enzyme (E-I’), which is defined by the rate constant kinact 
(Figure 6.34). This modified form of the inactivator I’ binds very tightly to the enzyme 
and is released very slowly from the enzyme active site (Figure 6.34). 
 
 
Figure 6.34: Kinetic model for the mechanism based inactivation. 
To obtain the kinetics of inactivation, we employed a strategy previously reported for 
mechanism based inactivators.
186, 187
 The activity of MqnE remaining after its incubation 
with the inhibitor 83 was determined. MqnE was incubated with different concentrations 
of 83 (ranging from 10 nm to 50 µM) for certain amount of time and then the enzyme 
was allowed to react with the native substrate, 53 in the presence of SAM and dithionite. 
An aliquot of the reaction mixture (50 µL) was quenched at different time intervals using 
8M guanidine hydrochloride. Protein was removed by ultracentrifugation and the 
reaction mixture was analyzed by HPLC for the formation of aminofutalosine, 64. The 
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amount of aminofutalosine formed was quantified based on a standard curve (Figure B4, 
Appendix B) and the log of % enzyme activity remaining was plotted against time for 
each of the concentrations of substrate 83. The slopes of these lines represent kapp. Then 
the reciprocal of kapp is plotted against the reciprocal of inhibitor concentration (I) to 
construct the Kitz-Wilson plot
186 
(Figure 6.35). From the slope and intercept of this plot, 
KI and kinact were determined to be 1.07 ± 0.05 µM and 1.28± 0.08 min
-1
 respectively. 
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Figure 6.35: Kitz –Wilson plot for the inhibitor 83 
From these kinetic parameters it is evident that the inhibitor 83  binds relatively tightly 
in the active site of MqnE and perhaps the compound 84 formed during the catalytic 
cycle of MqnE binds even tighter and is released very slowly. In such a case, native 
substrate 53 is unable to bind and formation of aminofutalosine is not observed. 
However, a crystal structure of MqnE with 83 bound at the active site would be very 
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informative in understanding the mechanism of inactivation. Moreover, it was also found 
in an in-vivo study (by Dinesh Simkhada, Figure B55, Appendix B) that compound 83 
inhibit the growth of Dienococcus radiodurans R1, an organism that synthesizes 
menaquinone by the futalosine dependent pathway with an IC50 value of 6.4mM. This 
large value of IC50 may be due to the fact that compound 83 cannot get into the cells 
very easily. It was also found that its growth could be recovered by the addition of 
menaquinone to the growth medium suggesting that this compound is a pathway specific 
inhibitor with the most likely target being MqnE (Figure B60, Appendix B). However, 
additional experiments would be required to determine the potency of this inhibitor 
using a pathogenic strain of bacteria that synthesizes menaquinone by the new pathway. 
Further attempts are in progress in understanding the inhibition mechanism of compound 
83 and its derivatives using biochemical and structural studies. 
Conclusion 
In summary, in this mechanistic study, several biochemical experiments were performed 
to test our proposed mechanism for MqnE (Figure 6.2). The captodative radical 69 
formed in the MqnE catalyzed reaction by the addition of the 5’-deoxyadenosyl radical 
on the double bond of the substrate was trapped using substrate analog 83 (Figure 6.5) 
and 88 (Figure 6.7). The support for the spirocylization step in the proposed mechanism 
is obtained by exploiting the competition reaction in which C-Br bond cleavage 
competes with reaction involving radical addition to the benzene ring using suitably 
designed substrate analogs 88, 96, 101a, 101b, 101c (Figure 6.25). Observation of 
substituent effects (Table 6.1) on the step involving radical addition to benzene ring 
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suggested intermediate radical character in the ring at positions 4 and/or 6 is consistent 
with the proposed spirocyclic intermediate 70 (Figure 6.2). 
 
Figure 6.2: Mechanistic proposal for the MqnE catalyzed reaction. 
Moreover, the alkoxy radical 71 proposed in the reaction mechanism after the radical 
rearrangement is also trapped by using the substrate analog 109 (Figure 6.26). 
Compound 83 was found to be an irreversible mechanism based inactivator of MqnE 
(Figure 6.33). The experimental results from the substrate analogs based mechanistic 
study were consistent with our proposed mechanism for this remarkable radical SAM 
enzyme reaction. In this regard, MqnE represents a unique motif in radical SAM 
enzymology in which the reactive 5’-deoxyadeonsyl radical is used as a substrate partner 
to form the C-C bond in the product aminofutalosine via a spirocyclic radical 
rearrangement mechanism.  
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Experimental procedures 
General methods and materials: All chemicals were purchased from sigma Aldrich (St. 
Louis, MO) unless otherwise stated and used without further purification. LB growth 
medium was obtained from Difco. Kanamycin, ampicillin, chloramphenicol antibiotics 
and isopropyl-β-D-thiogalactopyranoside (IPTG) were purchased from LabScientific 
Inc. Ni-Nitrilotriacetic acid (NTA) resin was from GE life sciences. E. coli M15 
(pREP4) competent cells were obtained from Qiagen. Molecular biology manipulations 
were carried out as previously reported.
64
 Centrifugal filters were obtained from Pall 
Life Sciences. Analytical HPLC (Agilent) was carried out using a Supelcosil LC-18- T 
HPLC reverse phase column (15 cm x 4.6 mm, 3 µM particle size). HPLC grade 
solvents were obtained from Fisher Scientific.  
Reverse phase HPLC method:  HPLC analysis using a linear gradient, at a flow rate of 1 
mL/min was used with absorbance detection at 254 nm.  Solvent A is water, solvent B is 
100 mM K2HPO4,  pH 6.6 (in some cases 5 mM ammonium acetate, pH 6.6 was used), 
and solvent C is methanol: 0 min, 100% B; 5 min, 100 % B; 12 min, 48 % A, 40 % B, 12 
% C; 14 min, 48 % A, 30 % B, 22 % C; 18 min, 32 % A, 10% B, 58% C; 20 min, 100 % 
B; 25 min 100 % B. 
Chiral HPLC method: The chiral column used was Chiralcel OD HPLC column in 
which the bulk stationary phase consisted of 20 µM silica support onto which the 
polymeric chiral selector, cellulose tris (3,5-dimethylphenylcarbamate) has been 
physically coated. The mixture of racemic methylated derivatives (44) were extracted to 
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ethylether after the diazomethane treatment and evaporated into dryness before 
dissolving in isopropanol to run on the chiral HPLC column. The mobile phase used was 
5% isopropanol and 95% hexane (isocratic solution) for a time period of about 25 min. 
LC-MS method: Samples were analyzed by reverse-phase HPLC on an Agilent 1200 
HPLC system equipped with a diode array UV-Vis detector and a thermostatted 
autosampler (10 °C). The stationary phase was Supelcosil LC-18-T (15 cm × 3 mm, 3 
µm particles size), maintained at 22 °C. The LC eluent consisted of a gradient of 75% 
methanol in 25% water with 5 mM ammonium acetate buffer, pH 6.6 (0.4 mL/min flow 
rate). The percentages of ammonium acetate buffer (B) and methanol (M) at time t varied 
according to the following scheme: {t,M,B}: {0,0,100}, {2,0,100}, {10,35,65}, 
{15,57.5,42.5}, {18,100,0}, {23,100,0}; {26,0,100}; {33,0,100}. Compounds were 
detected using absorbance at 254 nm. UV-Vis spectra (190 – 640 nm) were also 
collected and evaluated. Mass data were collected using an in-line Bruker Daltonics 
micrOTOF-Q II ESI-Qq-TOF mass spectrometer (HyStar) in positive or negative ion 
mode as indicated. 
NMR analysis: All NMR analyses were performed using a Bruker Avance III 500 MHz 
instrument with H−C−N Cryoprobe (1H 500 MHz, 13C 125 MHz) in 3 mm Wilmad 
labglass 535-PP-7 high precision NMR tubes at room temperature (22 °C) using 
standard instrument settings and processing parameters. 
Expression and purification of MqnE (His6-TTHA0804): Heterologous expression in 
and purification from E. coli M15 (pREP4) cells (Qiagen) was performed as previously 
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described
147
 except that the expression construct also contained pSUF
188
 (co-transformed 
with pQE-30 vector containing the ttha0804 gene) and 34 μg/mL of chloramphenicol 
was also added along with 40 µg/mL kanamycin and 100 µg/mL ampicillin during 
growth. The protein expression was initiated by adding IPTG to a final concentration of 
100 µM along with the supplementation of ferrous ammonium sulfate (100 mg/L) and l-
cysteine (100 mg/L). Protein purification was carried out in an anaerobic chamber (Coy 
Laboratories) containing 5% hydrogen and 95% nitrogen. Purified protein was buffered 
exchanged into the desalting Buffer (100 mM potassium phosphate, pH 7.5 at 25 °C, 2 
mM DTT, 30% glycerol) via Econo-Pac 10DG size exclusion chromatography (Bio-
Rad). Proteins were submerged in liquid nitrogen until use. 
MqnE activity assays: Reaction mixtures were set up as previously described.
147
 Briefly, 
the mixtures (100 µL) consisted of 50 µL solutions of 100 mM Tris-HCl buffer (pH 7.5), 
1.5 mM substrate analog, 2mM SAM, and 100 µM of MqnE (excess sodium dithionite). 
In some cases, biological reducing system (50 µM of FldA, 50 µM FldR and 2 mM 
NADPH) was also used in place of dithionite. The reaction was allowed to proceed for 
about 8-10 hrs, quenched with 8M guanidine hydrochloride and protein was removed by 
ultracentrifugation using Pall centrifugal devices before analyzing the reaction mixtures 
by HPLC and LCMS methods. 
Purification of the compounds formed in the substrate analogs reaction: Each reaction 
mixture (150 µL) contained chemically synthesized substrate analog, 88 (2 mM), S-
adenosylmethionine, 66 (2 mM), purified MqnE (200 µM) and excess sodium dithionite 
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in 100 mM Tris-HCl buffer, pH 7.5. The reaction was allowed to proceed anaerobically 
for about 10 hrs. The reaction was repeated multiple times to give sufficient product for 
analysis. The reactions were quenched with an equal volume of 8M guanidine 
hydrochloride and the protein was removed by ultrafiltration using 10 kDa centrifugal 
filters (Pall Life Sciences). Compounds 90 and 64 was purified from the reaction 
mixture by HPLC (eluted at 17.7 minutes and 19.2 minutes) using the HPLC method 
mentioned previously. The compound was buffer exchanged into 5mM ammonium 
acetate by HPLC. The purified product was concentrated using a speedvac concentrator 
(Thermo Scientific), dissolved in D2O and characterized by 
1
H and 
13
C NMR (Appendix 
B). Same procedure is applied for the purification of the compounds formed in the 
reactions using substrate analogs 96, 101a, 101b and 101c. 
Quantification of the compounds formed in the substrate analogs reaction: The 
compounds 90 and 64 formed in the reaction of the analog 88 were purified out from the 
reaction mixtures using HPLC and each sample were treated separately with 5M HCl 
and heated at 90°C for about 3 hrs. Upon this treatment, adenine was formed as a result 
of the breaking of the N-glycosyl bond which is common in both the structures. Hence, 
the amounts of adenine formed are directly proportional to the amounts of these 
compounds. The acid treated samples were neutralized and injected into the HPLC and 
the amounts of adenine formed from each compound were determined based on a 
standard curve of adenine (Appendix A). The quantification was repeated three times. 
Same procedure is applied for other substrate analogs 96, 101a, 101b and 101c. 
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CHAPTER VII 
SUMMARY AND CONCLUSIONS 
Pseudouridine catabolism 
Summary: The pseudouridine (Ѱ) catabolic pathway occurs in two steps: first 
pseudouridine is phosphorylated at the 5’-hydroxyl group by a kinase (YeiC) to form 
pseudouridine monophosphate (ѰMP) and then the latter is cleaved to form uracil and 
ribose 5-phosphate by the ΨMP glycosidase (YeiN). Structural studies performed on the 
ΨMP glycosidase provides four snapshots of the reaction coordinate which gave key 
mechanistic insights into the enzymatic hydrolysis of C-glycosides.  Most importantly, 
the structural studies suggested that the reaction involves an intermediate imine with 
Lys166 in the enzyme active site. The intact protein mass spectrometric studies, 
followed by the analysis of the trypsin digested fragments led to the confirmation of this 
finding. These studies allowed us to propose a reasonable mechanism for this 
glycosidase. The steady state kinetics analysis of the wild type YeiN and the active site 
mutants helped us to assign roles for specific amino acid residues that might be involved 
during catalysis. 
Conclusions: The biochemical and structural studies performed on the ΨMP glycosidase 
(YeiN) catalyzed transformation demonstrates that it utilizes a new kind of mechanism 
involving ribose ring opening and subsequent covalent linkage between C1′ of sugar 
moiety of ΨMP and an active site lysine (K166), thus setting the stage for a facile C-
glycosyl bond fragmentation reaction by a novel retro aldol type reaction mechanism. 
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Moreover, this enzyme also requires divalent metal ion cofactors for its function. In 
contrast, most glycosidases, characterized till date, utilize a dissociative mechanism to 
reversibly cleave C−N and C−O glycosidic bonds through the intermediacy of an 
oxocarbonium ion. During such a mechanism, the ring opening of the sugar moiety has 
never been observed and there is also no requirement for metal ion cofactors. In all these 
respects, ΨMP glycosidase deviates from the reported glycosidase chemistry so far. To 
the best our knowledge, this is the first mechanistically characterized example of a 
glycosidase that catalyzes the cleavage of a C-C glycosidic bond and probably many 
more examples of such kind are likely to emerge in the future providing new insights 
into their mechanisms and adding to the repertoire of rich glycosidase chemistry. 
Menaquinone Biosynthesis 
Summary: Menaquinone (vitamin K) is a lipid-soluble molecule that shuttles electrons 
between membrane-bound redox enzymes in the bacterial respiratory chain. It is also a 
very important vitamin in mammals where it participates as a cosubstrate in the 
carboxylation of glutamic acid residues in various proteins involved in blood coagulation 
and bone morphogenesis. Besides the classical pathway in Escherichia coli,
 
a new 
pathway for menaquinone biosynthesis was reported in Streptomyces coelicolor A3 (2). 
Except for the last two steps, all the other biosynthetic steps are completely different in 
this pathway from the classical pathway. We have recently reconstituted the early steps 
of this new pathway in vitro and revised the biosynthetic steps for the formation of 
futalosine, the first intermediate on this pathway. The pathway begins with MqnA 
catalyzing the transformation of chorismate into 3-[(1-carboxyvinyl) oxy]-benzoic acid 
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and then the newly discovered radical SAM enzyme MqnE catalyzes the transformation 
of the latter into aminofutalosine using radical mediated chemistry. 
We have proposed a mechanism for chorismate dehydratase, MqnA based on structural 
and biochemical studies. We believe that the carboxyl group of the pyruvate side chain 
of substrate chorismate is involved in this transformation. We have proposed a 
mechanism for the radical SAM enzyme MqnE catalyzed reaction. It involves addition 
of the reactive 5’-deoxyadenosyl radical on the enol ether double bond of the substrate to 
generate the captodative radical which further undergoes rearrangement to give the 
alkoxy radical via the spirocyclic radical intermediate. The alkoxy radical then loses 
carbon dioxide and an electron back to the [4Fe-4S] cluster to give aminofutalosine. In 
our mechanistic study, we have obtained several experimental results which are 
consistent with our proposed mechanism. We have trapped the captodative radical 
formed in the MqnE catalyzed reaction using substrate analog based chemistry. 
Moreover, evidence for the spirocylization step in the proposed mechanism is also 
obtained by exploiting the competition reaction in which carbon-halogen bond cleavage 
competes with the reaction involving radical addition to the benzene ring using a 
suitably designed substrate analog. Observation of substituent effects using substituted 
substrate analogs suggested intermediate radical character in the aryl ring at positions 4 
and/or 6 providing support for the intermediacy of a spirocyclic radical. Moreover, the 
alkoxy radical proposed in the reaction mechanism is also trapped by using the substrate 
analog based strategy. Currently, studies are underway to characterize the spirocyclic 
radical by electron paramagnetic resonance (EPR) spectroscopy (in collaboration with 
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David Britt lab, UC Davis) using N-oxide substrate analogs. Works are also in progress 
to determine the facial selectivity of radical addition. A probable mechanism based 
inactivator of MqnE is also uncovered during this study. Structural studies on MqnE are 
in progress (in collaboration with Juan Fontecilla lab, IBS, Grenoble, France) to 
visualize the active site architecture of this enzyme and relative spatial orientation of the 
native substrate or analogs and SAM in the active site to get further insights into the 
mechanism. 
Conclusions: In the study reported here, a new radical SAM enzyme is discovered to be 
involved in the alternative menaquinone biosynthesis pathway which led us to clarify the 
early steps of this pathway in contrast to the previous proposal. The mechanistic 
investigation on MqnE provided great insights into this remarkable radical SAM enzyme 
reaction. In this regard, MqnE represents a unique motif in radical SAM enzymology in 
which the reactive 5’-deoxyadeonsyl radical is used as a substrate partner to form the 
carbon-carbon bond in the product aminofutalosine. This is a new reaction motif in 
biological chemistry that employs a radical transposition mechanism via a spirocyclic 
radical intermediate during its catalytic cycle. 
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APPENDIX A 
 
Figure A1: HPLC analysis of the Pseudouridine kinase (YeiC) reaction mixture. Blue 
trace: Chromatogram of the full reaction (Ѱ,Psu + ATP + YeiC + Mg2+) 
Formation of ѰMP is observed at 2.1 min. Red trace: Chromatogram of the 
authentic standard of pseudouridine, Ѱ. 
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Figure A2: HPLC chromatogram of the coupled YeiC and YeiN assay. Blue trace: 
Chromatogram of the full reaction (Ѱ,Psu + ATP + YeiC + Mg2+ + YeiN + 
Co
2+
). Red trace: Chromatogram of the full reaction (Ѱ,Psu + ATP + YeiC + 
Mg
2+
 + YeiN + Mn
2+
).  Formation of uracil is observed at 3.9 min. Green trace: 
Chromatogram of the authentic standard of  uracil. Purple trace: Chromatogram 
of the authentic standard of   pseudouridine, Ѱ.  
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Figure A3: LC-MS spectrum of ѰMP, 9 
 
 
Figure A4: NMR spectrum of ѰMP, 9 
a 
b c, d, e, f 
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Michaelis-Menten polts for YeiN mutants 
 
Figure A5: Michaelis Menten plots ѰMP glycosidase and its mutants: YeiN (A), 
K166A B), E31A(C), K93A (D), and N289A (E 
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Table A1: Designed primers for YeiN mutants. 
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APPENDIX B 
 
Figure B1: 
1
H NMR spectra of [U-
13
C10]-chorismate isolated from E.coli KA-12. 
 +TOF MS: 0.033 to 0.167 min from 06111204a.wiff
a=3.56385948403262310e-004, t0=-1.99374788813511260e+001 R;
Max. 4.9 counts.
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Figure B2: ESI MS (positive mode) of [U-
13
C10]-chorismate 
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MRGIRDPRLIPIAEKVMEGKRLSFEDGLVLYQTKDLPTLMRLANLVRERKHGHK
TYFVHSIRVSQTNICYVGCTFCAFQRRFGEEGAWDWDVDEVVAWVKERYQPG
LTEIHLTAGHHPKRPFAYYLDLVRALKENFPGVQVKAWTAAEIHHFSKIARLPY
REVLKALKEAGLDAMPGGGAEIFAERVRRKIARAKVSAEGWLEIHRTAHELGIP
TNATMLYGHIETLEERLDHMDRLRRLQDETGGFMSFIPLAFQPDGNQLARELGK
KEFTTGLDDLRNLAVARLYLDNFPHIKGYWATLTPELAQVSLDWGVTDVDGTL
IEERIVHMAGSPTPQGLTKRELARIILMAGRIPVERDALYREVRVWDRVEA 
 
Figure B3: Sequence of TTHA0804 protein (MqnE) from T. thermophilus HB8. 
 
 
 
Figure B4: Standard curve for aminofutalosine, 64. 
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Figure B5: 
1
H NMR (500 MHz, D2O) of compound 84. 
 
 
 
Figure B6:
 13
C NMR (125 MHz, D2O) spectrum of compound 84. 
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Figure B7: 
1
H COSY spectrum of compound 84. 
 
 
 
 
 
Figure B8:
 13
C DEPT-90 NMR (125 MHz, D2O) spectrum of compound 84. 
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Figure B9:
 13
C DEPT-135 NMR (125 MHz, D2O) spectrum of compound 84. 
 
 
 
Figure B10: HSQC spectrum of compound 84 
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Figure B11: Incorporation of deuterium into compound 84 
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Figure B12: SDS-PAGE gel MqnE: A) Protein maeker B) Wild type MqnE C) and D) 
MqnE after reaction with 83, E) MqnE in no substrate control F) MqnE in no SAM 
control G) MqnE in no dithionite control. 
 
 
 
Scheme B1: Synthetic scheme for the substituted substrate analogs. 
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Figure B13: 
1
H NMR (500 mHz, D2O) of compound 98 
 
 
 
 
Figure B14: COSY spectrum of compound 98. 
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Figure B15: 
13
C NMR (125 mHz, D2O) of compound 98 
 
 
 
 
 
 
Figure B16: 
13
C DEPT-NMR (125 mHz, D2O) of compound 98 
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Figure B17: HSQC spectrum of compound 98. 
 
 
 
 
 
Figure B18: 
1
H NMR (500 mHz, D2O) of compound 100 
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Figure B19: COSY spectrum of compound 100. 
 
 
Figure B20: DEPT-135 spectrum of compound 100 
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Figure B21: Standard curve for adenine. 
 
 
 
 
 
 
Figure B22: 
1
H NMR (500 MHz, D2O) spectrum of compound 103a. 
 
 190 
 
 
 
Figure B23: 
1
H-COSY spectrum of compound 103a 
476.1220
+MS, 8.2-8.3min #(492-498), Background Subtracted
0.0
0.5
1.0
1.5
2.0
2.5
3.0
4x10
Intens.
300 320 340 360 380 400 420 440 460 480 m/z  
 
Figure B24: LC-MS (ESI, positive ion mode). In the mass spectrum, m/z 476.1219, 
[M+H]
+
 corresponds to compound 103a (theoretical m/z 476.1219)  
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Figure B25: 
1
H NMR (500 MHz, D2O) spectrum of compound 103b. 
 
 
Figure B26: 
1
H-COSY spectrum of compound 103b 
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Figure B27: LC-MS (ESI, positive ion mode). In the mass spectrum, m/z 476.1219, 
[M+H]
+
 corresponds to compound 103b (theoretical m/z 476.1219)  
 
 
 
 
 
Figure B28: 
1
H NMR (500 MHz, D2O) spectrum of compound 103c. 
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Figure B29: 
13
C NMR (125 MHz, D2O) spectrum of compound 103c 
 
 
 
Figure B30: 
13
C DEPT-135 NMR (125 MHz, D2O) spectrum of compound 103c. 
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Figure B31: 
1
H-COSY spectrum of compound 103c 
 
 
Figure B32: HSQC spectrum of compound 103c. 
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Figure B33: LC-MS (ESI, positive ion mode). In the mass spectrum, m/z 476.1218, 
[M+H]
+
 corresponds to compound 103c (theoretical m/z 476.1219) 
 
 
 
 
 
Figure B34: 
1
H NMR (500 MHz, D2O) spectrum of compound 105a. 
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Figure B35: 
13
C NMR (125 MHz, D2O) spectrum of compound 105a 
 
 
Figure B36: 
1
H-COSY spectrum of compound 105a 
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Figure B37: HSQC spectrum of compound 105a. 
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Figure B38: LC-MS (ESI, positive ion mode). In the mass spectrum, m/z 432.1333, 
[M+H]
+
 corresponds to compound 105a (theoretical m/z 432.1323)  
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Figure B39: 
1
H NMR (500 MHz, D2O) spectrum of compound 105b. 
 
 
 
 
 
 
Figure B40: 
13
C NMR (125 MHz, D2O) spectrum of compound 105b 
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Figure B41: 
1
H-COSY spectrum of compound 105b 
 
 
Figure B42: HSQC spectrum of compound 105b. 
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Figure B43: LC-MS (ESI, positive ion mode). In the mass spectrum, m/z 432.1322, 
[M+H]
+
 corresponds to compound 105b (theoretical m/z 432.1323)  
 
 
 
 
 
Figure B44: 
1
H NMR (500 MHz, D2O) spectrum of compound 105c. 
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Figure B45: 
13
C NMR (125 MHz, D2O) spectrum of compound 105c 
 
 
 
 
 
Figure B46: 
13
C DEPT 135 NMR spectrum of compound 105c 
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Figure B47: 
1
H-COSY spectrum of compound 105c 
 
 
Figure B48: HSQC spectrum of compound 105c. 
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Figure B49: LC-MS (ESI, positive ion mode). In the mass spectrum, m/z 432.1330, 
[M+H]
+
 corresponds to compound 105c (theoretical m/z 432.1323). 
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no substrate_1-C,2_01_17291.d: UV Chromatogram, 254 nm  
 
Figure B50:LC-MS chromatogram of the MqnE reaction mixture using 114 as substrate. 
Pink trace: Full reaction (114 + MqnE+ SAM + dithionite), Red trace: no dithionite 
control, Yellow trace: No enzyme control, Gray trace: no substrate control reactions 
(The compound eluting at 14.5 min is 5’-deoxyadenosine,116) 
 
5’-deoxyadenosine 
Compound 117 
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Figure B51:LC-MS chromatogram of the MqnE reaction mixture using 114 as substrate 
(The compound eluting at 11 min is identified as 117 by comparing with a reference 
standard as shown by the yellow trace) 
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Figure B52: LC-ESI MS of reference standard (m/z 165.0547 [M+H]
+
) 
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Scheme B2: Synthetic scheme for compound 117. 
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Figure B53: Co-migration with an authentic standard of 5’-deoxyadenosine in the MqnE 
assay with substrate analogue, 114. 
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Facial selectivity of the adenosyl radical addition: 
Since the methyl group of 114 must be pointing at the 5’-deoxyadenosyl radical 67 for 
hydrogen abstraction to occur, hence identifying the correct enantiomer of 114 (R or S) 
that is the substrate for MqnE would tell us if radical 67 adds to the top or bottom face of 
the double bond of substrate 53 in the native reaction (Figure B54). 
 
 
Figure B54: A stereochemical model for the radical addition reaction 
 
To investigate this hypothesis, racemic 114 were treated with diazomethane in diethyl 
ether to convert it to the methylated derivatives, 118 and the resulting protected 
enantiomers were separated on a normal phase chiral HPLC column, the enantiomers 
eluting at 7 min and 11.5 min in 1:1 ratio (Figure B55). 
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Figure B55: Separation of enantiomers of the racemic methylated derivatives, 118. 
 
In the next experiment, the racemate substrate 114 (1.5 mM) was treated with MqnE 
(100 uM) in presence of SAM (2 mM) and excess dithionite and reaction was allowed to 
proceed for about 8 hrs. The enzyme was removed by ultracentrifugation and the 
unreacted substrate 114 was separated from the reaction mixture by HPLC purification. 
This unreacted substrate was then treated with diazomethane to convert it to the methyl 
esters and the resulting racemic protected derivatives mixture was then run on the 
normal phase chiral column The ratio of enantiomers of 118 was observed to be 0.5:1 in 
this case(Figure B56). This suggested that the enantiomer of substrate 114 whose methyl 
ester elutes at 7 min in the HPLC chromatogram was preferentially consumed in the 
MqnE reaction. By comparing with the HPLC chromatogram of the enantiomers of the 
synthesized methylated derivatives (Figure B57 and B58), it was found that the S isomer 
was the preferred substrate for MqnE. 
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Figure B56: Separation of enantiomers of the methylated derivatives of the unreacted 
substrate after the MqnE reaction 
 
 
Figure B57: Synthetic scheme for enantiomeric methylated derivatives. 
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Figure B58: Separations of mixture enantiomers of synthesized methylated derivatives 
of 114 with R isomer being in excess (eluting at 10.8 min) 
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Figure B59: MqnE reaction with 1:1 mixture of 53 and 88 (Pink trace), 53 and 114 
(Brown trace), 53 and 83 ( Grey trace) and only 53 (Blue trace). Inhibition was observed 
only in the case of 83 as indicated by the levels of aminofutalosine produced. 
Aminofutalosine 
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Figure B60: D. radiodurans R1 growth study (Tryptic Soy Broth, Temperatures used 
30°C and 37°C) in presence of the inhibitor 83. The growth can be recovered by addition 
of menaquinone (MK-4) to the culture medium (by Dinesh Simkhada, Begley lab, 
unpublished results). 
